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Summary 
Introduction 
Health Problem 
According to the International Headache Society (IHS), migraine is a prima-
ry headache disorder described by periodic attacks of headache, typically ac-
companied by loss of appetite, nausea, vomiting, sensitivity to light, to noise 
or to odor, and movement hypersensitivity [1]. Migraine has two major types, 
migraine with aura and migraine without aura. Both may share the above 
symptoms, while migraine with aura also includes transient focal neurologi-
cal symptoms that may precede or accompany a headache [2]. The difference 
between episodic migraine (EM) and chronic migraine (CM) essentially lies 
in frequency of headache days [1]. While in EM, headaches occurs less than 
15 times per month, in CM, headaches must occur more than 15 times per 
month in the last three consecutive months. 
According to Global Burden of Disease 2015, migraine was ranked to be the 
third-highest cause of disability worldwide in both males and females under 
the age of 50 years [2]. EM affects more than 10% of the population and has 
higher prevalence in women (18%) than in men (6%) [1]. CM affects 1-5% of 
the general population [1]. As migraine is essentially a cerebral disorder, the 
major cause of EM and CM is genetics [3]. The progression from EM to CM 
develops at a rate of about 2.5% per year, yet migraine patients show a great 
intra-individual variability and so also move back from CM to EM [4]. 
Description of Technology 
The external trigeminal nerve stimulator (e-TNS) (Cefaly®) is an intervention 
that stimulates the upper nerve branch (supraorbital nerve) of the trigeminal 
nerve with the aim of reducing the frequency and length of migraine attacks 
[5]. The supraorbital nerve ends at the vertex of the scalp, thus providing sen-
sory innervation to the forehead, upper eyelid, and anterior scalp. The self-
adhesive e-TNS electrode is placed at the forehead targeting the supraorbital 
nerve [6]. The battery-operated electrical pulse generator connects magneti-
cally to the electrode from where it conducts electrical micro-pulses [5]. The 
e-TNS is either used for the prevention of a migraine attack through daily 20 
minute sessions, or it is used for acute treatment as a 60 or 120 minutes long 
intervention during the migraine attack. The pulse width of 250 μs and max-
imum intensity of 16 mA is the same for both modes, but the preventive mode 
has the pulse frequency of 60 Hz, while the acute treatment mode has 100 Hz [5]. 
In 2014, the e-TNS device was approved by the FDA as a Class II medical 
device for the indication of “prophylactic treatment of episodic migraine in 
patients over the age of 18” [7], and in 2017, FDA granted also the acute mi-
graine treatment approval [8]. According to information provided by the man-
ufacturer, the e-TNS (Cefaly®) device also bears a CE mark in Europe from 
January 2008 for the broad indication of headaches. 
The claimed benefit of e-TNS is the reduction of the frequency and length of 
migraine attacks. E-TNS claims to be less invasive, have a better effectiveness-
safety ratio, less side effects, no serious side effects, and fewer contraindica-
tions. Furthermore, it claims to reduce the acute anti-migraine drug intake, 
thus preventing medication overuse headache. 
migraine: primary 
headache disorder, 
migraine with aura and 
migraine without aura, 
episodic (EM) and 
chronic migraine (CM) 
migraine: third-highest 
cause of disability under 
50 years of age in 2015, 
EM has higher 
prevalence in women,  
a cerebral disorder,  
main cause is genetics 
e-TNS: stimulates the 
supraorbital nerve with 
micro-impulses both for 
prevention as well as 
acute treatment of EM 
and CM 
e-TNS approved by FDA 
for both prevention as 
well as acute treatment, 
holds a CE-mark in 
Europe for the 
indication of headaches 
claimed benefit: 
reduction of migraine 
attacks and drug intake, 
less invasive, no serious 
side effects 
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Methods 
The aim of this systematic review was to investigate whether e-TNS, as a pre-
ventive or acute therapy, is more effective and safer than standard drug thera-
py or placebo with respect to improvement in migraine episodes, quality of 
life (QoL), satisfaction, and side effects. The EUnetHTA Core Model for 
Rapid Assessment of Relative Effectiveness was the main source for select-
ing relevant assessment elements. 
The systematic literature search was conducted in the following four data-
bases (Medline via Ovid, Embase, The Cochrane Library, CRD (DARE, NHS-
EED, HTA)). The search was not limited to a year of publication, but it was 
limited to prospective studies and articles published in English or German. 
After deduplication, overall 433 citations were included. 
Furthermore, the following clinical trial registries were assessed for registered 
ongoing clinical trials or observational studies (ClinicalTrials.gov, WHO-
ICTRP, EU Clinical Trials) yielding 70 results, of which seven were relevant. 
The only manufacturer of e-TNS (Cefaly®) submitted 19 publications of which 
four were unpublished at the time of writing of the report and hence were 
confidential and not included. No new citations were identified. By hand-
search, additional seven publications were found, resulting in overall 440 hits. 
 
Results 
Available evidence 
For the assessment of clinical effectiveness, two studies met the inclusion cri-
teria. One randomized controlled trial (RCT) for the preventive use of e-TNS 
[9] and one RCT for the acute treatment use of e-TNS [10]. Both compared 
the e-TNS (Cefaly®) to a sham (Cefaly®) device. The latter was not in the form 
of a peer-reviewed publication, but in the form of a study protocol and study 
results published at clinicaltrials.gov [10]. The studies were sponsored by 
the manufacturer STX Med – Cefaly® Technology or by the Walloon Region 
(where the manufacturer provided the e-TNS devices), respectively. In the 
preventive study, the length of follow-up was 90 days and it included 67 pa-
tients (34 received e-TNS) [9]. While in the acute treatment study, the follow-
up was 24 hours and it included 106 patients (52 received e-TNS) [10]. 
For the assessment of safety, seven studies met the inclusion criteria. Two 
RCTs (described above [9, 10]), and five prospective case series (three for 
prevention with the total of 84 patients [11-13] and two for acute treatment with 
the total of 95 patients [14, 15]). One of the case series studies was not in the 
form of a peer-reviewed publication, but in the form of a study protocol and 
study results published at clinicaltrials.gov [15]. Three were sponsored by 
STX Med – Cefaly® Technology [13-15] and in the remaining two, the source 
of funding was unclear, but it was stated that the devices were provided by 
the manufacturer [11, 12]. In the preventive case series studies, the length of 
follow-up ranged from 60 to 120 days [11-13], while in the acute treatment case 
series studies, the follow-up was 24 hours [14, 15]. 
aim: is e-TNS vs. 
standard therapy or 
placebo more effective 
and safer 
systematic literature 
search in four databases, 
422 hits 
search in clinical trial 
registries for ongoing 
trials, 70 hits, 7 relevant 
19 publications from  
the manufacturer,  
4 confidential,  
hand-search yielded  
7 hits 
2 RCTs for effectiveness: 
1 for prevention  
(90 days follow up) and 
1 for acute treatment 
(24 hours follow-up), 
comparator:  
placebo, sponsored  
by STX Med – Cefaly® 
Technology  
7 studies for safety,  
2 RCTs and  
5 prospective case series, 
3 for prevention  
with 60 and 120 days  
of follow-up,  
2 for acute treatment 
with 24 hours follow-up 
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Clinical effectiveness 
Concerning prevention, the results from the RCT (34 e-TNS patients) suggest 
that e-TNS is more effective than sham treatment in EM patients when 
measured by reduction of migraine attacks (0.67 less migraine attacks per 
month), migraine days (1.74 less migraine days per month), headache days 
(2.28 less headache days per month), acute antimigraine drug intake (4.24 
less instances of acute drug intake per month), improvement in responder 
rate of migraine days (26.2% more response to verum treatment) and satis-
faction (31.2% difference in satisfaction with the control group) [9]. 
Concerning acute treatment, the RCT showed that e-TNS caused more im-
provement in pain reduction than sham on a VAS scale (out of 11 points) at 
1/2/24 hours post-acute treatment (1.68/1.02/1.08 more improvement points, 
respectively) [10]. Concerning the minimal clinically important difference 
(MCID), however, it remains unclear if the improvement measured is of 
clinical importance because the results oscillate around the lower end of the 
clinically meaningful benefit threshold [16]. There was also an increase of 
one intervention group (IG) patient in acute antimigraine drug intake at two 
hours post-acute treatment compared to control (CG), but a decrease of three 
verum patients compared to control at 24 hours [10]. 
Safety 
Concerning safety, in both prevention and acute treatment studies, no serious 
adverse device effects occurred. 
In terms of adverse device effects in the prevention studies, two studies re-
ported that there were none [9, 12], while intolerance to paraesthesia (burn-
ing sensation) was reported in 34.3% of patients in [13]. Furthermore, head-
ache after stimulation as well as neck tension were reported in one study [11], 
where headache occurred in 8.7% of patients, while there was neck tension 
in 4.3%. 
In terms of adverse device effects in the acute treatment studies, one study re-
ported that there were none [14, 15], while intolerance to paraesthesia was 
documented in two acute treatment studies in 5.8% (IG n=52) vs. 1.9% (CG 
n=54) [10] and 11.9% of patients [15]. Nausea after stimulation was report-
ed in two studies in 1.9% (IG n=52) vs. 0% (CG n=54) [10] and 3.5% of pa-
tients [15]. 
Furthermore, arousal changes (insomnia, sleepiness/fatigue, drowsiness), diz-
ziness, vomiting, pain in the jaw, discomfort in teeth, pain in eyes, and cold 
feet occurred in one study all in 1.7% of patients [15]. In the same study, 
18.3% of patients reported skin allergy/irritation. 
Upcoming evidence 
Currently, there is only one ongoing RCT for the acute treatment use of e-TNS 
that aims to recruit 600 patients with an estimated primary completion date 
of October 2018 (NCT03465904). 
Reimbursement 
The e-TNS is currently not reimbursed in the Austrian setting as part of the 
Austrians social health insurance coverage. As stated by the manufacturer, 
Cefaly® is reimbursed in the Netherlands, Switzerland, and in the USA for 
Veterans by Tricare. 
prevention: e-TNS more 
effective than placebo  
in reduction of migraine 
attacks, migraine days, 
headache days, 
responder rate, and 
satisfaction 
acute treatment:  
e-TNS more effective 
than placebo in 
improving pain 
reduction at 1/2/24 hours 
post-acute treatment, 
MCID questionable, 
unclear in reduction of 
antimigraine drug intake 
no serious adverse 
device effects occurred 
in any of the studies 
adverse device effects  
in prevention studies: 
intolerance to 
paraesthesia, headache 
after stimulation,  
neck tension 
skin allergy/irritation 
adverse device effects in 
acute treatment studies: 
intolerance to para-
esthesia, nausea after 
stimulation, arousal 
changes (insomnia, 
sleepiness/fatigue, 
drowsiness), dizziness, 
vomiting, pain in the 
jaw, discomfort in teeth, 
pain in eyes, cold feet, 
1 ongoing RCT for  
the acute treatment 
(end in October 2018) 
e-TNS is not reimbursed 
in Austria 
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Discussion 
Concerning the effectiveness (RCTs) of prevention and acute treatment with e-
TNS, the quality of evidence was low to very low. The main reasons were the 
small sample size, uncertainty about sufficient reporting of adverse device 
effects, and the wrong comparator. Concerning safety, the quality of evi-
dence ranged from high, moderate, to low and very low (as two case-series 
were judged to have a high risk of confounding as co-interventions were ei-
ther not clearly described [13], or it was clearly stated that preventive as well 
as acute treatments for CM were not changed during the study [11]). 
In terms of outcomes, standardized evaluation of satisfaction and quality of 
life was lacking, and the follow-up of 24 hours that was applied to all three 
acute treatment studies is considered short. Also, consistency of the effect of 
e-TNS is undermined because in medication studies, several attacks must be 
treated in one person to prove that the acute therapy works and that was not 
the case. 
In terms of generalizability of the data, the prevention studies represent the 
real clinical context, as the patients used the e-TNS in their homes, but the 
acute treatment studies were conducted in the hospital setting, yet the e-TNS 
should be used in the home setting for acute treatment as well. Compliance is 
considered to be one of the key issues as in the preventive RCT [9], it was 
61.7% (IG) vs. 54.4% (CG) and it was not reported in the acute treatment 
RCT [10]. In the survey with 2,313 patients, 46.6% of patients were unsatis-
fied who, in terms of compliance, used the device for the recommended pe-
riod of time only in 48.6% of cases [17]. 
While e-TNS has the potential to improve patients’ autonomy and reduce the 
total medication intake, its non-invasive nature needs to be put in the con-
text of the paucity of knowledge about its mechanism of action and thus its 
long term safety profile. It is not clear to what extent the electrical field ap-
plied in such close proximity to the brain for an extended period of time in-
fluences the brain. Furthermore, the potential cost-effectiveness of e-TNS as-
sociated with its potential improvement in economic productivity of migraine 
patients [18] needs to be contrasted with the small effects measured by the 
VAS. 
Furthermore, given the small size of the highly selective sample of patients 
included in the evidence base (as compared to the large burden of disease that 
migraine creates), the conclusions about effectiveness and the positive safety 
profile are considered to be inflated. The target population of e-TNS are not 
only patients refractory to medication, but mainly drug responsive patients, 
which makes e-TNS aim to replace the use of medication. That is why larger 
controlled trials with best practice interventions (for prevention as well as acute 
treatment use of e-TNS) as comparators are necessary for potentially consid-
ering e-TNS to be part of the standard practice. 
 
Recommendation 
The inclusion in the catalogue of benefits is currently not recommended. 
 
quality of evidence  
for effectiveness (RCTs): 
low to very low, quality 
of evidence for safety 
(case series and RCTs): 
high, moderate, low, 
very low 
no standardized 
evaluation of satisfaction 
and quality of life,  
24 hours follow-up for 
acute therapy too short 
prevention studies 
represent real clinical 
context – e-TNS used  
at home, not the case 
for acute treatment, 
problem with 
compliance 
advantages: 
improvement in patient 
autonomy, reduction in 
medication intake, non-
invasive, economic 
savings; disadvantages: 
unclear mechanism of 
action, unclear long-term 
safety profile, small 
effects on VAS 
 
conclusions about 
effectiveness and 
positive safety profile 
are considered inflated, 
target population are 
also drug responsive 
patients and hence an 
RCT with best practice 
comparators necessary 
e-TNS currently not 
recommended in the 
catalogue of benefits 
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Zusammenfassung 
Einleitung 
Gesundheitsproblem 
Laut der International Headache Society (IHS) ist Migräne eine primäre 
Kopfschmerzstörung, die durch periodische Attacken von Kopfschmerzen be-
schrieben wird und typischerweise von Appetitlosigkeit, Übelkeit, Erbrechen, 
Lichtempfindlichkeit und Lärm oder Geruch und Bewegungsüberempfind-
lichkeit begleitet wird [1]. Es können zwei Haupttypen unterschieden werden: 
Migräne mit Aura und Migräne ohne Aura. Beide Typen können die oben 
genannten Symptome umfassen, während mit Migräne mit Aura auch vo-
rübergehende fokale neurologische Symptome einhergehen können, die Kopf-
schmerzen vorausgehen oder begleiten können [2]. Der Unterschied zwischen 
episodischer Migräne (EM) und chronischer Migräne (CM) liegt im Wesent-
lichen an der Häufigkeit der Kopfschmerztage [1]. Während bei einer EM 
Kopfschmerzen an weniger als 15 Tage pro Monat auftreten, liegt bei einer 
CM eine Häufigkeit von mehr als 15 Mal Kopfschmerzen pro Monat in den 
letzten drei aufeinander folgenden Monaten auf. 
Nach dem Global Burden of Disease 2015 wurde Migräne sowohl bei Män-
nern als auch bei Frauen unter 50 Jahren als weltweit dritthäufigste Ursache 
von Invalidität eingestuft [2]. EM betrifft mehr als 10 % der Bevölkerung und 
hat eine höhere Prävalenz bei Frauen (18 %) als bei Männern (6 %) [1]. CM 
betrifft 1-5% der Allgemeinbevölkerung [1]. Da Migräne im Wesentlichen ei-
ne zerebrale Störung ist, wird angenommen, dass die Hauptursache von EM 
und CM in der Genetik liegt [3]. Die Progression von EM zu CM entwickelt 
sich mit einer Rate von etwa 2,5 % pro Jahr, MigränepatientInnen zeigen je-
doch eine große intraindividuelle Variabilität und somit auch eine Rückent-
wicklung von CM zu EM [4]. 
Beschreibung der Technologie 
Bei der Anwendung des externe Trigeminus-Nervenstimulator (e-TNS) (Ce-
faly®) wird der obere Nervenast (N. supraorbitalis) des Trigeminusnervs sti-
muliert, um die Häufigkeit und Dauer von Migräneattacken zu reduzieren 
[5]. Der N. supraorbitalis endet an der Spitze der Kopfhaut, wodurch die 
Stirn, das obere Augenlid und die vordere Kopfhaut sensorisch innerviert wer-
den. Die selbstklebende e-TNS-Elektrode wird stirnseitig auf den N. supra-
orbitalis gelegt [6]. Der batteriebetriebene elektrische Impulsgenerator ver-
bindet sich magnetisch mit der Elektrode und leitet von dort elektrische Mi-
kroimpulse ab [5]. Das e-TNS wird entweder zur Vorbeugung einer Migrä-
neattacke durch tägliche 20-minütige Sitzungen oder als akute Behandlungs-
methode für jeweils 60 oder 120 Minuten lange Interventionen während ei-
ner Migräneattacke verwendet. Die Pulsbreite von 250 μs und die maximale 
Intensität von 16 mA sind für beide Modi gleich, wohingegen sich die Puls-
frequenz zwischen präventiver und akuter Behandlung unterscheidet: wäh-
rend der präventiven Behandlung arbeitet das Gerät mit einer Pulsfrequenz 
von 100 Hz und im akuten Behandlungsmodus mit 60 Hz [5]. 
Migräne = primäre 
Kopfschmerzstörung, 
Migräne mit Aura vs. 
Migräne ohne Aura, 
episodische Migräne 
(EM) vs. chronische 
Migräne (CM) 
Migräne = dritthäufigste 
Invaliditätsurlache 
weltweit,  
EM häufiger bei Frauen, 
Hauptursache in der 
Genetik 
e-TNS – Nerven-
stimulation des  
N. supraorbitalis  
durch elektrische 
Mikroimpulse als 
Präventionstherapie 
oder Akuttherapie 
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Im Jahr 2014 wurde das e-TNS-Gerät von der FDA als Medizinprodukt der 
Klasse II für die Indikation „prophylaktische Behandlung von episodischer 
Migräne bei PatientInnen über 18 Jahren“ zugelassen [7]. Im Jahr 2017 be-
willigte die FDA auch die akute Migränebehandlung mit dem e-TNS-Gerät 
[8]. Nach Angaben des Herstellers trägt das e-TNS (Cefaly®)-Gerät seit Jän-
ner 2008 auch in Europa die CE-Kennzeichnung für die breite Indikation 
Kopfschmerzen. 
Der erwartete Vorteil von e-TNS ist die Verringerung der Häufigkeit und 
Dauer von Migräneattacken. Zusätzlich scheint das Gerät weniger invasiv zu 
sein, da es ein besseres Verhältnis von Effektivität und Sicherheit, weniger 
Nebenwirkungen, keine ernsthaften Nebenwirkungen und weniger Kontra-
indikationen vorweisen soll. Darüber hinaus wird behauptet, dass die akute 
Einnahme von Anti-Migräne-Medikamenten durch die Anwendung von e-TNS 
reduziert wird, wodurch Kopfschmerzen durch Medikamentenübergebrauch 
verhindert werden könnten. 
 
Methoden 
Ziel dieser systematischen Übersichtsarbeit war es, zu untersuchen, ob e-TNS 
als präventive oder akute Therapie wirksamer und sicherer ist als eine me-
dikamentöse Standardtherapie oder eine Placebo-Therapie hinsichtlich der 
Verbesserung von Migränepisoden, der Lebensqualität, der Zufriedenheit 
und der Nebenwirkungen. Das EUnetHTA-Core-Modell für schnelle Asses-
sments zur relativen Wirksamkeit war die wichtigste Quelle für die Auswahl 
relevanter Bewertungselemente. 
Die systematische Literatursuche wurde in den folgenden vier Datenbanken 
durchgeführt (Medline via Ovid, Embase, The Cochrane Library, CRD (DA-
RE, NHS-EED, HTA)). Die Suche beschränkte sich nicht auf ein Publikati-
onsjahr, jedoch auf prospektive Studien und Artikel in englischer oder deut-
scher Sprache. Nach der Deduplizierung wurden insgesamt 433 Zitate gezählt. 
Darüber hinaus wurden die folgenden klinischen Studienregister (Clinical-
Trials.gov, WHO-ICTRP, EU-klinische Studien) für die Suche nach regis-
trierte laufende klinische Studien oder Beobachtungsstudien herangezogen. 
Die Suche ergab 70 Ergebnisse, von denen sieben relevant waren. 
Der einzige Hersteller von e-TNS (Cefaly®) reichte 19 Veröffentlichungen ein, 
von denen vier zum Zeitpunkt der Verfassung des Berichts noch nicht veröf-
fentlicht waren und daher vertraulich behandelt wurden. Keine neuen Zitate 
wurden identifiziert. Bei der Handsuche wurden weitere sieben Publikatio-
nen gefunden, was insgesamt 440 Treffer ergab. 
 
Ergebnisse 
Verfügbare Evidenz 
Zur Beurteilung der klinischen Wirksamkeit erfüllten zwei Studien die Ein-
schlusskriterien. Eine randomisierte kontrollierte Studie (RCT) für die prä-
ventive Verwendung von e-TNS [9] und ein RCT für die Akutbehandlung 
mit e-TNS [10]. Beide verglichen das e-TNS (Cefaly®) mit einem Placebo-
Gerät. Das RCT zur Akuttherapie [10] erfolgte nicht in Form einer begut-
achteten Publikation, sondern in Form eines Studienprotokolls und der Stu-
dienergebnisse, die bei clinicaltrials.gov veröffentlicht wurden. Die Studien 
wurden vom Hersteller STX Med – Cefaly® Technology oder von der Wallo-
nischen Region (wo der Hersteller die e-TNS-Geräte anbietet) gesponsert. In 
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19 Veröffentlichungen 
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der präventiven Studie [9] betrug die Nachbeobachtungszeit 90 Tage und um-
fasste 67 PatientInnenen (34 erhielten e-TNS). Während die Nachbeobach-
tungszeit der akuten Behandlungsstudie [10] 24 Stunden betrug und 106 Pa-
tientInnen (52 erhielten e-TNS) umfasste. 
Zur Beurteilung der Sicherheit erfüllten sieben Studien die Einschlusskrite-
rien. Diese umfassten die zwei oben beschriebenen RCTs [9, 10], und fünf 
prospektive Fallserien (drei zur Prävention mit insgesamt 84 Patienten [11-
13] und zwei zur Akutbehandlung mit insgesamt 95 Patienten [14, 15]). Eine 
der Fallserienstudien [15] wurde nicht in Form einer Peer-Review-Veröffent-
lichung, sondern in Form eines Studienprotokolls und der Studienergebnis-
se bei clinicaltrials.gov veröffentlicht. Drei der Fallserienstudien [13-15] wur-
den von STX Med – Cefaly® Technology gesponsert. Bei den Übrigen [11, 12] 
war die Finanzierung unklar, es wurde jedoch angegeben, dass die Geräte 
vom Hersteller bereitgestellt wurden. In den präventiven Fallserienstudien 
[11-13] lag die Nachbeobachtungsdauer zwischen 60 und 120 Tagen, wäh-
rend in den Akutbehandlungsstudien [14, 15] die Nachbeobachtungszeit bei 
24 Stunden lag. 
Klinische Wirksamkeit 
Bezüglich der Präventionsbehandlung mit e-TNS zeigten die Ergebnisse der 
RCT (34 e-TNS-PatientInnen), dass die Behandlung mit e-TNS bei EM-Pa-
tientInnen wirksamer ist als die Placebo-Behandlung, gemessen durch die Re-
duktion der Migräneanfälle (0,67 weniger Migräneattacken pro Monat), Mig-
ränetage (1,74 weniger Migränetage pro Monat), Kopfschmerztage (2,28 we-
niger Kopfschmerztage pro Monat), akute Anti-Migräne-Medikamentenein-
nahme (4,24 weniger Fälle von akuter Medikamenteneinnahme pro Monat) 
und Steigerung der Responderrate (26,2 % mehr Reaktion auf e-TNS-Behand-
lung) und der Zufriedenheit (31,2 % Unterschied in der Zufriedenheit mit 
der Kontrollgruppe) [9]. 
In Bezug auf die Akutbehandlung mit e-TNS zeigte das RCT, dass e-TNS 
eine Verbesserung der Schmerzreduktion auf einer VAS-Skala (von 11 Punk-
ten) nach 1/2/24 Stunden nach der Akutbehandlung im Vergleich zur Pla-
cebo-Behandlung bewirkte (Reduktion um 1,68/1,02/1,08 VAS-Punkte) [10]. 
Bezüglich des minimalen, klinisch wichtigen Unterschieds (MCID) bleibt 
jedoch unklar, ob die gemessene Verbesserung auf der VAS-Skala von klini-
scher Bedeutung ist, da die Ergebnisse um das untere Ende der klinisch re-
levanten Nutzenschwellenwerte schwanken [16]. Es gab auch eine Zunahme 
von einem Patienten in der Interventionsgruppe bezüglich der akuten Anti-
Migräne-Medikamenteneinnahme zwei Stunden nach der akuten e-TNS-Be-
handlung im Vergleich zur Kontrolle, aber eine Abnahme von drei Patien-
tInnen im Vergleich zur Kontrolle nach 24 Stunden [10]. 
Sicherheit 
Was die Sicherheit betrifft, so traten sowohl in den Studien zur Vorbeugung 
als auch in der Akutbehandlung keine schwerwiegenden Nebenwirkungen 
auf. 
In zwei Präventionsstudien kam es auch zu keinen sonstigen Nebenwirkun-
gen [9, 12], wohingegen bei 34,3 % der PatientInnen in [13] eine Intoleranz 
gegenüber Parästhesien berichtet wurde. Darüber hinaus wurden in einer 
Studie Kopfschmerzen nach der Stimulation (8.7 % der PatientInnen), sowie 
Nackenverspannungen (4.3 %) berichtet [11]. 
7 Studien für Sicherheit: 
2 RCTs und 5 
prospektive Fallserien – 
3 Prävention mit 60 und 
120 Tagen Follow-up 
und 2 Akuttherapie mit 
24h Follow-up 
Prävention:  
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 Verbesserung der 
Schmerzempfindung  
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24h nach e-TNS Therapie 
keine schwerwiegenden 
Nebenwirkungen in 
keiner Studie 
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Im Hinblick auf Nebenwirkungen in den Akutbehandlungsstudien berichte-
te eine Studie, dass es zu keinen Nebenwirkungen kam [14, 15], während ei-
ne Intoleranz gegenüber Parästhesien in zwei Akutbehandlungsstudien bei 
5,8% (IG n = 52) vs. 1,9 % (CG n = 54) [10] und 11,9 % der PatientInnen 
auftrat [15]. Übelkeit nach der Stimulation wurde in zwei Studien in 1,9 % 
(IG n = 52) gegenüber 0 % (CG n = 54) [10] und 3,5 % der PatientInnen be-
richtet [10]. 
Darüber hinaus traten in 1,7 % der Fälle Sensibilitätsveränderungen (Schlaf-
losigkeit, Schläfrigkeit/Müdigkeit, Benommenheit), Schwindel, Erbrechen, 
Kieferschmerzen, Zahnbeschwerden, Augenschmerzen und kalte Füße auf 
[10]. In derselben Studie berichteten 18,3 % der PatientInnen über eine Haut-
allergie/-reizung. 
Laufende Studien 
Zurzeit gibt es lediglich ein laufendes RCT für die Akutbehandlung von e-
TNS, das 600 PatientInnen umfasst, die mit einem geschätzten primären Ab-
schlussdatum im Oktober 2018 rekrutieren werden sollen (NCT03465904). 
Kostenerstattung 
Die Kosten für das e-TNS Gerät werden derzeit im Rahmen der österreichi-
schen gesetzlichen Krankenversicherung in Österreich nicht erstattet. Wie 
vom Hersteller angegeben, wird Cefaly® in den Niederlanden, der Schweiz 
und in den USA für Veterans by Tricare erstattet. 
 
Diskussion 
In Bezug auf die Wirksamkeit (RCTs) von e-TNS war die Qualität der Evi-
denz (Prävention und Akutbehandlung) niedrig bis sehr niedrig. Die Haupt-
gründe dafür waren der kleine Stichprobenumfang, die Unsicherheit bezüg-
lich ausreichender Berichterstattung von Nebenwirkungen und die Wahl des 
falschen Komparators. Bezüglich der Sicherheit von e-TNS, reichte die Qua-
lität der Evidenz von hoch, moderat, zu niedrig und sehr niedrig. Zwei Fall-
serien weisen ein hohes Risiko von Störvariablen auf, da Kointerventionen 
entweder nicht eindeutig beschrieben wurden [13], oder klar festgehalten 
wurde, dass sowohl präventive als auch akute CM-Behandlungen während 
der Studie nicht verändert wurden [11]. 
In Bezug auf die gewählten Endpunkte fehlte eine standardisierte Bewertung 
für Zufriedenheit und Lebensqualität. Das Follow-up Intervall von 24 Stun-
den, das in allen drei Akutbehandlungsstudien angewendet wurde, wird als 
zu kurz erachtet. Außerdem wurde die Bestätigung der Wirkung von e-TNS 
geschwächt, da in Medikationsstudien mehrere Migräneattacken bei einer 
Person behandelt werden müssen, um zu beweisen, dass die Akuttherapie 
funktioniert und dies aber nicht der Fall war. 
Bezüglich der Generalisierbarkeit der Daten stellen die Präventionsstudien 
den tatsächlichen klinischen Kontext dar, da die PatientInnen das e-TNS in 
ihrem Zuhause anwenden konnten. Die Akutbehandlungsstudien wurden je-
doch im Krankenhaus durchgeführt. Auch für die Akutbehandlungsstudien 
sollte das e-TNS in häuslicher Umgebung angewendet werden. Compliance 
wird als eines der Hauptprobleme angesehen, wie im präventiven RCT [9] 
veranschaulicht: 61,7 % (IG) vs. 54,4 % (CG). Im Akutbehandlungs-RCT wur-
den keine Compliance-Raten berichtet [10]. Eine Befragung mit 2.313 Pati-
entInnen ergab, dass 46,6 % der PatientInnen unzufrieden mit dem e-TNS-
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Gerät waren. Die PatientInnen nutzten das Gerät (in Bezug auf Compliance) 
lediglich in 48,6 % der Fälle für den empfohlenen Zeitraum [17]. 
e-TNS hat zwar den Vorteil, die Autonomie der PatientInnen zu verbessern 
und die Gesamteinnahme von Medikamenten zu reduzieren. Jedoch muss 
die nicht-invasive Natur in den Kontext des Mangels an Wissen über den 
Wirkungsmechanismus und somit über das langfristige Sicherheitsprofil ge-
stellt werden. Es ist nicht klar, in welchem Ausmaß das elektrische Feld, das 
in solch einer Nähe zum Gehirn für eine längere Zeit angewendet wird, das 
Gehirn beeinflusst. Darüber hinaus muss die potentielle Kosteneffektivität 
von e-TNS, die mit einer potenziellen Verbesserung der wirtschaftlichen Pro-
duktivität von MigränepatientInnen in Zusammenhang steht [18], mit den 
kleinen Auswirkungen verglichen werden, die von der VAS ableitbar sind. 
Insgesamt werden die Schlussfolgerungen über die Wirksamkeit und das po-
sitive Sicherheitsprofil des e-TNS-Geräts als überhöht angesehen. Begründet 
wird dies aufgrund der kleinen Größe der hochselektiven PatientInnenstich-
probe (verglichen mit der großen Krankheitslast, die Migräne verursacht). 
Die Zielpopulation von e-TNS sind nicht nur PatientInnen, die refraktär auf 
Medikamente reagieren, sondern ebenso auf Arzneimittel ansprechende Pa-
tientInnen, um zu untersuchen, in welchem Ausmaß e-TNS eine Verringe-
rung der Medikamenteneinnahme mit sich bringt. Aus diesem Grund sind 
größere kontrollierte Studien mit Best-Practice-Interventionen (zur Präven-
tion und zur Akutbehandlung von e-TNS) als Komparatoren erforderlich, um 
e-TNS möglicherweise als Teil der Standardpraxis zu betrachten. 
 
Empfehlung  
Die Aufnahme in den Leistungskatalog wird derzeit nicht empfohlen. 
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aufgrund zu kleiner 
Stichprobengröße im 
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Migräne, größere RCTs 
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Interventionen als 
Vergleichstherapie 
erforderlich 
e-TNS derzeit  
nicht für Aufnahme  
in den Leistungskatalog 
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1 Scope 
1.1 PICO question 
Is the e-TNS, as a preventive or acute therapy, in comparison to placebo or 
the standard therapy (triptan, NSAIDs/paracetamol, or combination of trip-
tan together with NSAIDs/paracetamol for acute treatment or topiramate 
and propranolol for prevention) in patients with episodic or chronic migraine 
more effective or equally effective concerning improvement in migraine epi-
sodes, quality of life (QoL), and satisfaction; and safer regarding the side ef-
fects? 
 
 
1.2 Inclusion criteria 
Inclusion criteria for relevant studies are summarized in Table 1-1. 
Table 1-1: Inclusion criteria 
Population Prophylactic or acute therapy in adult patients with episodic and chronic migraine. 
MeSH-term: Headache Disorders, Migraine Disorders 
ICD-10 code: G43.909 
Intervention External trigeminal nerve stimulation (e-TNS) Supraorbital transcutaneous  
nerve stimulation (s-TNS) – original name changed after GMDN code to e-TNS 
Product name: Cefaly® 
MeSH-term: Trigeminal Nerve, Electrical Stimulation 
Control Acute treatment: 
 NSAIDs/Paracetamol 
 Triptan  
 Triptan + NSAIDs/Paracetamol 
 Placebo 
MeSH-term: Anti-Inflammatory Agents, 
Non-Steroidal 
Prevention: 
 Topiramate 
 Propranolol 
 Placebo 
MeSH-term: Propranolol, Topiramate 
Outcomes  
Efficacy Crucial outcomes for the preventive use of e-TNS: 
 Reduction in monthly migraine days 
 Reduction in monthly acute antimigraine drug intake 
 Satisfaction 
Crucial outcomes for the acute treatment use of e-TNS: 
 Change in pain score units on VAS scale compared to baseline at 1/2/24 hours 
 Patients on acute antimigraine medication at 2/24 hours 
 Satisfaction 
Further outcomes for the preventive use of e-TNS: 
 Reduction in monthly migraine attacks 
 Reduction in monthly headache days 
 Responder rate 
 QoL 
 Compliance 
 
PIKO-Frage 
Einschlusskriterien  
für relevante Studien 
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Efficacy 
(continuation) 
Further outcomes for the acute treatment use of e-TNS: 
 Headache pain free patients at 2/24 hours post-acute treatment 
 Improvement in nausea, vomiting, sensitivity to light and sound at 2 hours 
 QoL 
 Compliance 
Safety Crucial Serious adverse device effects (SADEs) for both  
preventive and acute treatment use of e-TNS: 
 SADEs 
Further Adverse device effects (ADEs) for both  
preventive and acute treatment use of e-TNS: 
 Pain/intolerance to paraesthesia (burning sensation) 
 Arousal changes (insomnia, sleepiness/fatigue) 
 Headaches after stimulation 
 Skin allergy 
 Neck tension 
 Nausea after stimulation  
 Dizziness 
 Vomiting 
 Pain in the jaw 
 Discomfort in teeth 
 Pain in eyes 
 Cold feet 
Study design  
Efficacy Randomised controlled trials 
Prospective non-randomised controlled trials 
Safety Randomised controlled trials 
Prospective non-randomised controlled trials 
Prospective case-series 
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2 Methods 
2.1 Research questions 
Description of the technology 
Element ID Research question 
B0001 What is e-TNS and the comparator(s)? 
A0020 For which indications has e-TNS received marketing 
authorisation or CE marking? 
B0002 What is the claimed benefit of e-TNS in relation to the 
comparators? 
B0003 What is the phase of development and implementation  
of e-TNS and the comparator(s)? 
B0004 Who administers e-TNS and the comparators and in what 
context and level of care are they provided? 
B0008 What kind of special premises are needed to use e-TNS  
and the comparator(s)? 
B0009 What supplies are needed to use e-TNS and the comparator(s)? 
A0021 What is the reimbursement status of e-TNS? 
 
Health problem and Current Use 
Element ID Research question 
A0001 For which health conditions, and for what purposes is e-TNS used? 
A0002 What is the disease or health condition in the scope  
of this assessment? 
A0003 What are the known risk factors for episodic/chronic migraine? 
A0004 What is the natural course of episodic/chronic migraine? 
A0005 What is the burden of disease for the patients with 
episodic/chronic migraine? 
A0006 What are the consequences of episodic/chronic migraine  
for the society? 
A0024 How is the disease or health condition currently diagnosed 
according to published guidelines and in practice? 
A0025 How is the episodic/chronic migraine currently managed 
according to published guidelines and in practice? 
A0007 What is the target population in this assessment?  
A0023 How many people belong to the target population? 
A0011 How much is e-TNS utilised? 
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Clinical Effectiveness 
Element ID Research question 
D0001 What is the expected beneficial effect of e-TNS on mortality? 
D0003 What is the effect of e-TNS on the mortality due to causes other 
than the target disease? 
D0005 How does e-TNS affect symptoms and findings  
(severity, frequency) of the disease or health condition? 
D0006 How does e-TNS affect progression (or recurrence) of the 
disease or health condition? 
D0011 What is the effect of e-TNS on patients’ body functions? 
D0016 How does the use of e-TNS affect activities of daily living? 
D0012 What is the effect of e-TNS on generic health-related  
quality of life? 
D0013 What is the effect of e-TNS on disease-specific quality of life? 
D0017 Was the use of e-TNS worthwhile? 
 
Safety 
Element ID Research question 
C0008 How safe is e-TNS in comparison to the comparator(s)? 
C0002 Are the harms related to dosage or frequency of applying e-TNS? 
C0004 How does the frequency or severity of harms change over time 
or in different settings? 
C0005 What are the susceptible patient groups that are more likely  
to be harmed through the use of e-TNS? 
C0007 Are e-TNS and comparator(s) associated with  
user-dependent harms? 
B0010 What kind of data/records and/or registry is needed to monitor 
the use of e-TNS and the comparator(s)? 
 
 
2.2 Sources 
Description of the technology 
 Handsearch in the POP, AdHopHTA and CRD databases  
for Health Technology Assessments 
 Background publications identified in database search: see Section 2.3 
 Documentation provided by the manufacturer 
Health problem and Current Use 
 Handsearch in the POP, AdHopHTA and CRD databases  
for Health Technology Assessments 
 Handsearch of clinical guideline (AHRQ, Up-to-date,  
EBM guidelines) 
 Background publications identified in database search: see Section 2.3 
 Documentation provided by the manufacturer 
 
Quellen 
Methods 
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2.3 Systematic literature search 
The systematic literature search was conducted  
in the following four databases:  
 Medline via Ovid 
 Embase  
 The Cochrane Library 
 CRD (DARE, NHS-EED, HTA) 
The systematic search was not limited to a year of publication. The search 
was limited to prospective studies and articles published in English or Ger-
man. After deduplication, overall 433 citations were included. The specific 
search strategy employed can be found in the Appendix.  
Furthermore, the following clinical trial registries were assessed for regis-
tered ongoing clinical trials or observational studies: ClinicalTrials.gov, 
WHO-ICTRP, EU Clinical Trials. The search yielded 70 results, of which 7 
were relevant to the research question under assessment. For detailed search 
strategies, see the appendix. 
The only manufacturer of e-TNS (Cefaly®) submitted 19 publications of which 
4 were unpublished at the time of writing of the report and hence were con-
fidential and not included. No new citations were identified.  
By hand-search, additional 7 publications were found, resulting in overall 
440 hits. 
 
 
  
systematische 
Literatursuche in  
4 Datenbanken  
Einschränkungen nach 
Studiendesign und 
Sprache 
433 Hits 
Suche nach laufenden 
klinischen Studien 
keine zusätzlichen 
Publikationen durch 
Hersteller 
nach Handsuche  
440 Treffer 
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2.4 Flow chart of study selection 
Overall 441 hits were identified. The references were screened by three in-
dependent researchers and all disagreements were solved through discussion. 
The selection process is displayed in Figure 2-1. 
 
Figure 2-1: Flow chart of study selection (PRISMA Flow Diagram) 
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2.5 Analysis 
The data retrieved from the selected studies were systematically extracted 
into a data-extraction-table (see Appendix Tables A-1 to A-4). No further da-
ta pro-cessing (e.g. indirect comparison) was applied. Three independent re-
searchers (MS, SW, HJ) systematically assessed the quality of evidence (see 
Tables 7-1 and 7-2) and the risk of bias (RoB) using the checklists presented 
in the Appendix Tables A-5 and A-6). 
 
 
2.6 Synthesis 
Based on the data-extraction-table (see Appendix Tables A-1 to A-4), data on 
each selected outcome category were synthesised across studies according to 
GRADE (Grading of Recommendations Assessment, Development and Eval-
uation) [36]. The research questions were answered in plain text format with 
reference to GRADE evidence tables (see Tables 7-1 and 7-2). 
 
 
Datenextraktion und 
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und der Evidenzstärke 
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Datensynthese auf 
Outcome-Level mittels 
GRADE 
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3 Description and technical 
characteristics of the technology 
Features of the technology and comparators 
B0001 – What is e-TNS and the comparator(s)? 
The external trigeminal nerve stimulator (e-TNS) (Cefaly®) is an intervention 
that stimulates the upper nerve branch (supraorbital nerve) of the trigeminal 
nerve (the fifth cranial nerve) with the aim of reducing the frequency and 
length of migraine attacks [5]. The supraorbital nerve ends at the vertex of 
the scalp, thus providing sensory innervation to the forehead, upper eyelid, 
and anterior scalp. The self-adhesive e-TNS electrode is placed at the forehead 
targeting the supraorbital nerve [6]. The battery-operated electrical pulse gen-
erator connects magnetically to the electrode from where it conducts electri-
cal micro-pulses to the upper branch of the trigeminal nerve (see Figure 3-1) 
[5]. The e-TNS is either used for the prevention of a migraine attack through 
daily 20-minute-sessions, or it is used for acute treatment as a 60 or 120 minutes 
long intervention during the migraine attack. The pulse width of 250 μs and 
maximum intensity of 16 mA is the same for both modes, but the preventive 
mode has the pulse frequency of 60 Hz, while the acute treatment mode has 
100 Hz [5]. 
 
Figure 3-1: e-TNS (Cefaly®) electrode and electrical pulse generator. 
There is a lack of clarity about the pathophysiology of migraine and hence 
also about the exact mechanism of action of e-TNS. One assumption is that 
migraine attacks are triggered by the physiological communication between 
first cervical spinal nerve roots and the spinal trigeminal tract [19]. The ap-
plication of e-TNS to the supraorbital nerve is then supposed to use this nerve 
pathway to spread the impulse from the frontalis muscle to peripheral mus-
cles, which may make it recorded in other muscles far from the application 
area [19]. In this way, the e-TNS could act therapeutically on the inhibitory 
circuit in the spinal cord causing a neuromuscular facilitation and a reduc-
tion in contractions of frontalis muscles [19]. Alternatively, another assump-
tion is that e-TNS exerts its beneficial effects via slow neuromodulation of 
central pain-controlling areas [20]. It is assumed that it reduces the hypome-
tabolism of the orbitofrontal cortex as well as the rostral parts of the anterior 
cingulate cortex as the metabolic activity in these areas is decreased in mi-
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graine [20]. Furthermore, e-TNS may interfere with the threshold and the 
extent of trigeminal system activation, thus resolving or preventing migraine 
attacks [21]. 
Alternative treatments concern both prevention as well as acute treatment of 
episodic (EM) as well as chronic migraine (CM). In terms of treatment, most 
EM patients with few migraine attacks can be managed with acute therapy 
such as over the counter nonsteroidal anti-inflammatory drugs (NSAIDs) or 
paracetamol. Those can be taken alongside prescription medication in the class 
of triptans or vasoactive medication (dihydroergotamine) [1]. Both NSAID’s/ 
paracetamol as well as triptans/dihydroergotamine are used as monothera-
pies, while combination use is only recommended if necessary [1]. 
The main group of candidates for preventive treatment are those patients who 
have contraindications or severe adverse events associated with acute medi-
cations, or those with infrequent, but very severe and lengthy attacks [1]. 
Preventive treatment options for EM include non-drug interventions such as 
acupuncture, relaxation, cognitive behavioural therapy, or stress management 
[22].  
In Austria, first line preventive treatment options include Metoprolol, Pro-
pranolol, Flunarizin, Topiramate, and Valproat, while second-line substanc-
es are Amitriptylin, Sartane, Venlafaxin [23]. Preventive treatment options 
for CM are the injection of Onabotulinumtoxin A [1].  
There are also other alternative neuromodulation interventions for both EM 
and CM that are not part of standard clinical practice such as non-invasive 
single pulse transcranial magnetic stimulation, transcranial direct current 
stimulation, or non-invasive vagus nerve stimulation [24]. Invasive neuro-
modulation techniques include occipital nerve stimulation [24]. 
Non-invasive single pulse transcranial magnetic stimulation (TMS) is an in-
tervention that has been in use over 30 years for the treatment of depression, 
epilepsy, movement disorders of neurorehabilitation [24]. It is applied exter-
nally to the scalp through the use of a coil that creates a fluctuating magnet-
ic field, inducing an ionic current to the underlying cortex. The current then 
aims to change the firing pattern and excitability of cortical neurons [24]. 
While single pulse claims to depolarize neurons, repetitive pulse stimuli 
claim to modify the plasticity of the cerebral cortex even in remote areas in-
ducing functional activation or deactivation in the brain [22]. A recent sys-
tematic review of TMS suggests that its evidence base consists of five RCTs 
with the total of 313 patients concluding the TMS’ effectiveness [25]. 
Transcranial direct current stimulation (DCS) is a neuromodulation tech-
nique that, similarly to TMS, can cause reversible changes of the excitability 
of neurons by acting on their membrane potential when applied to the cor-
tex [24]. The evidence base for DCS is small as a sham RCT showed no sig-
nificant effect of DCS and its only data come from a proof of concept case 
series study with ten patients in whom the frequency of migraine attacks was 
claimed to be reduced [24]. 
Non-invasive vagus nerve stimulation (VNS) is an intervention with an un-
clear mechanism of action and a small evidence base [22, 24]. The main hy-
pothesis is the afferent anatomical connection between the vagus nerve and 
the trigeminal nucleus caudalis as well as the nociceptive inputs from the 
dura mater terminating in the nucleus tracturs solitarius could justify an as-
cending antinociceptive effect of the vagus nerve on the trigeminal nuclear 
complex (thus influencing migraine attacks) [24]. 
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Invasive occipital nerve stimulation (ONS) aims to inhibit nociceptive activ-
ity in small c-fiber and A-delta fibers through the stimulation of the occipi-
tal nerve [22]. The occipital nerve originates at the base of the neck where 
the ONS device is connected with leads to a power source. Centrally, ONS 
reduces activation of brain regions involved in pain processing and thus may 
improve migraine symptoms. The evidence base for ONS includes four mul-
ticentre RCTs where some conclude that it does while others that it does not 
improve migraine symptoms in statistically significant ways [22].  
A0020 – For which indications has e-TNS received marketing 
authorisation or CE marking? 
In 2014, the e-TNS device was approved by the FDA as a Class II medical 
device for the indication of “prophylactic treatment of episodic migraine in 
patients over the age of 18”. Furthermore, the FDA stated in 2012 that “the 
Cefaly® device should not be used by an individual with chronic migraine, 
refractory migraine, medication overuse headache, or chronic tension-type 
headaches” [7], but in 2017 granted also the acute migraine treatment approv-
al [8]. According to information provided by the manufacturer, the e-TNS 
(Cefaly®) device also bears a CE mark in Europe from January 2008 for the 
broad indication of headaches.  
B0002 – What is the claimed benefit of e-TNS  
in relation to the comparators? 
The claimed benefit of e-TNS is the reduction of the frequency and length of 
migraine attacks. When compared to pharmacological therapy for both EM 
and CM patients, e-TNS claims to be less invasive, have a better effectiveness-
safety ratio, less side effects, no serious side effects, and fewer contraindica-
tions. Thus, allegedly, it provides an acute treatment option for EM patients 
who refuse medication. Furthermore, e-TNS claims to reduce the acute anti-
migraine drug intake, thus preventing medication overuse headache (MOH), 
providing an acute treatment option to drug refractory patients, and thus pos-
sibly postponing/preventing deterioration of EM to CM. 
B0003 – What is the phase of development  
and implementation of e-TNS? 
It is a novel technology that is in its emerging phase with its pilot study pub-
lished in 2009, hence it is not part of standard clinical practice [26]. The cur-
rent device is the second generation that is identical to the first one in terms 
of function, but that changed the latching mechanism of the pulse generator 
onto the electrode to be magnetic. 
By 2018, there have been a total of seven prospective clinical studies published 
on the prevention and acute treatment both EM as well as CM. 
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Administration, Investments, personnel and  
tools required to use the technology and the comparator(s) 
B0004 – Who administers e-TNS and the comparator(s) and  
in what context and level of care are they provided? 
B0008 – What kind of special premises are needed to use e-TNS  
and the comparator(s)? 
The e-TNS is administered in the home setting by patients, which requires no 
special premises to be used for the administration of e-TNS. In terms of its 
distribution, the official distributor is the Belgian manufacturer CEFALY®-
Technology. In Germany, it is BOSANA Medizintechnik GmbH [37] and in 
Austria, the company Linde. 
B0009 – What supplies are needed to use e-TNS and the comparator(s)? 
The supplies needed for the use of e-TNS are a set of self-adhesive electrodes 
and the e-TNS device. 
 
Regulatory & reimbursement status  
A0021 – What is the reimbursement status of e-TNS? 
The e-TNS is currently not reimbursed in the Austrian setting as part of the 
Austrian social health insurance coverage. As stated by the manufacturer, 
Cefaly® is reimbursed in the Netherlands, Switzerland, and in the USA for 
Veterans by Tricare. 
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4 Health Problem and Current Use 
Overview of the disease or health condition 
A0001 – For which health conditions, and for what purposes is e-TNS used? 
A0002 – What is the disease or health condition in the scope of this 
assessment?  
The e-TNS is used for both prevention and acute treatment of EM as well as 
CM patients. According to the International Headache Society (IHS), mi-
graine is a primary headache disorder described by periodic attacks of head-
ache, typically accompanied by collateral symptoms, such as loss of appetite, 
nausea, vomiting, sensitivity to light (photophobia), to noise (phenophobia) 
or to odor, and movement hypersensitivity [1]. Migraine has two major types, 
migraine with aura and migraine without aura. Both may share the above 
symptoms, while migraine with aura also includes transient focal neurologi-
cal symptoms that may precede or accompany a headache [2]. 
The difference between EM and CM lies in frequency of headache days [1]. 
While EM is defined as migraine with or without aura that occurs less than 
15 times per month, CM is defined by headaches that occur more than 15 
times per month in the last three consecutive months of which eight or more 
days meet criteria for migraine with or without aura and/or respond to mi-
graine-specific treatment. Furthermore, these symptoms must occur in a pa-
tient with a lifetime history of at least five prior migraine attacks not attribut-
ed to another causative disorder and no medication overuse [2]. 
A0003 – What are the known risk factors for episodic/chronic migraine? 
A0004 What is the natural course of episodic/chronic migraine? 
As migraine is essentially a cerebral disorder, the major cause of EM and CM 
is genetics [3]. The progression from EM to CM, however, develops at a rate 
of about 2.5% per year. Important to note, however, is that a substantial num-
ber of patients also converts back from CM to EM and hence, the relation-
ship between the two is not only one way [4]. Migraine patients show a great 
intra-individual variability in the frequency of migraine attacks [4]. 
Furthermore, migraine tends to peek in midlife and can be caused by further 
modifiable and non-modifiable factors [1]. Modifiable factors include obesi-
ty, snoring, low educational level, and low socioeconomic status, stressful life 
events, asthma, allergic rhinitis, head and neck injury, and comorbid depres-
sion [1]. Non-modifiable factors include older age, female gender, Caucasian 
ethnicity, genetics, and the presence of cutaneous allodynia [1]. 
Migraine is a chronic disease that can occur over an individual’s lifetime. 
Migraine attacks usually last between four to 72 hours and can be triggered 
by a variety of factors such as stress, menstruation, birth control pills, physi-
cal exertion and fatigue, lack of sleep, hunger, head trauma, and certain foods 
or drinks that contain chemicals such as nitrites, glutamate, aspartate, tyra-
mine. It can be further triggered by specific medications and chemicals that 
include nitroglycerin, estrogens, hydralazine, perfumes, smoke, and organic 
solvents with a strong odor [27]. 
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Effects of the disease or health condition  
on the individual and society 
A0005 – What is the burden of disease  
for patients with episodic/chronic migraine? 
According to Global Burden of Disease 2015, migraine was ranked to be the 
third-highest cause of disability worldwide in both males and females under 
the age of 50 years [2]. EM affects more than 10% of the population and has 
higher prevalence in women (18%) than in men (6%) [1]. CM affects 1-5% 
of the general population and compared to EM, CM patients tend to experi-
ence more headache related disability, decreased headache-related quality of 
life (HRQoL), greater healthcare utilization, and higher levels of anxiety and 
depression [22]. The main burden of disease lies in periodic attacks of head-
ache that are typically associated with accompanying symptoms listed above. 
A0006 – What are the consequences  
of episodic/chronic migraine for the society? 
The consequences of EM and CM for the society lie not only in the costs re-
lated to mainly pharmacological treatment, but also in the costs from a soci-
etal perspective (economic costs) that are present when migraine attacks im-
pede on a person’s life, particularly on work activity. That is especially true 
because on the high prevalence on migraine in general and the fact that the 
highest incidence of migraine attacks occurs between the 35th and 45th year 
of life in particular. The main part of this economic burden is borne by em-
ployers who have to cover for the reduced workplace productivity that makes 
75-90% of the total economic cost of migraine [18]. 
 
Current clinical management of the disease or health condition 
A0024 – How is episodic/chronic migraine currently diagnosed  
according to published guidelines and in practice? 
For the diagnosis of migraine, the International Classification of Headache 
Disorders 3rd edition (ICHD-3) criteria are used as the common tool [2]. The 
ICHD-3 criteria distinguish between EM that can be with or without aura, 
and CM. 
The diagnostic criteria for migraine without aura are: 
 A. At least five attacks fulfilling criteria B-D 
 B. Headache attacks lasting 4-72 hours  
(untreated or unsuccessfully treated) 
 C. Headache with at least two of the following four characteristics: 
 unilateral location 
 pulsating quality 
 moderate or severe pain intensity 
 aggravation by or causing avoidance of routine physical activity 
(eg, walking or climbing stairs) 
 D. During headache at least one of the following symptoms occur: 
 nausea and/or vomiting 
 photophobia and phonophobia 
 E. Not better accounted for by another ICHD-3 diagnosis. 
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The diagnostic criteria for migraine with aura are: 
 A. At least five attacks fulfilling criteria B and C 
 B. One or more of the following fully reversible aura symptoms: 
 visual 
 sensory 
 speech and/or language 
 motor 
 brainstem 
 retinal 
 C. At least three of the following six characteristics: 
 at least one aura symptom spreads gradually over ≥5 minutes 
 two or more aura symptoms occur in succession 
 each individual aura symptom lasts 5-60 minutes 
 at least one aura symptom is unilateral 
 at least one aura symptom is positive 
 the aura is accompanied, or followed within 60 minutes,  
by headache 
 D. Not better accounted for by another ICHD-3 diagnosis. 
The diagnostic criteria for CM are: 
 A. Headache (migraine-like or tension-type-like) on ≥15 days/month 
for >3 months, and fulfilling criteria B and C 
 B. Occurring in a patient who has had at least five attacks fulfilling 
criteria B-D for migraine without aura and/or criteria B and C for 
migraine with aura. 
 C. On ≥8 days/month for >3 months, fulfilling any of the following 
criteria: 
 criteria C and D for migraine without aura 
 criteria B and C for migraine with aura 
 believed by the patient to be migraine at onset and relieved  
by a triptan or ergot derivative 
 D. Not better accounted for by another ICHD-3 diagnosis. 
Diagnosis is further made by collecting a typical medical history, family history, 
and neurological examination. Specific diagnostic examinations do not exist. 
A0025 – How is episodic/chronic migraine currently managed  
according to published guidelines and in practice? 
The current management option of EM and CM include both, drug and non-
drug interventions. 
The guideline of the German Society for Neurology and the German Society 
for Migraine and Headache suggests to use analgesics as the first line acute 
treatment for mild migraine attacks (ASS, Ibuprofen, Metamizol, Diclofenac-
Kalium, Paracetamol) [23]. For medium and severe migraine attacks, they 
further recommend the use of triptan (5-HT1B/1D-Agonists) therapy (almo-
triptan, eletriptan, frovatriptan, sodium rizatriptan, rizatriptan, sumatriptan 
and zolmitriptan) [23]. In emergency acute treatment of an attack, Metoclo-
plamid with Lysin-Acetylsalicylat or Sumatriptan are recommended [23].  
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In cases when monotherapy is insufficient, combining a triptan with an NS-
AID is superior to monotherapy [23, 28]. Such combination therapy is rec-
ommended by NICE as the first line acute treatment of migraine attacks [29]. 
Furthermore, antiemetics such as Domperidon and Metoclopramid are rec-
ommende for the treatment of nausea and vomiting [1, 23]. The efficacy of 
non-drug therapies has been poorly studied and so, pharmacological therapy 
outlined above remains to be the standard acute migraine treatment. 
In case of frequent migraine attacks or migraine attacks with pronounced 
symptoms, a migraine prophylaxis should be started [23]. Migraine prophy-
lactic drugs of first choice with strong evidence base are the beta-blockers 
(metoprolol and propranolol) [29], the calcium antagonist flunarizine, the an-
ticonvulsants topiramate and valproic acid, amitryptilin, and onabotulinum-
tofin A (for chronic migraine) [23].  
Drug therapy should be supplemented with lifestyle interventions (regular 
aerobic outdoor sports,) and non-drug behavioural therapies (relaxation pro-
cedures, cognitive behavioural therapy) [23]. Patients with high-frequency 
migraine attacks and significant impairment of QoL should use psychologi-
cal pain therapy (pain management, stress management, stress relief) [23]. 
As additional or alternative options to drug therapy recommended for pro-
phylaxis are non-invasive neuromodulation techniques, occipital nerve blocks, 
and invasive neuromodulation (in refractory migraine cases) [23]. 
 
Target population 
A0007 – What is the target population in this assessment? 
The target population of this assessment are adult patient of more than 18 
years of age with episodic as well as chronic migraine. 
A0023 – How many people belong to the target population?  
As outlined in A0005, EM affects more than 10% of the population and has 
higher prevalence in women (18%) than in men (6%) [1], while CM affects 
1-5% [22]. The manufacturer Cefaly® forecasts to sell +/- 150 device units 
per year and per million of population with the maximum plateau of 500 units 
per year and per million. Applying this to the Austrian context, in the popu-
lation of 8.7 million, approximately 1.300 devices are expected to be sold. 
A0011 – How much is e-TNS utilised? 
As the e-TNS is only used in the private sector, the answer to this question is 
not available. E-TNS is marketed and publicly available in online shops for 
approximately 300,- Euro   
(https://www.humacentris.de/produkt-kategorie/migraenetherapie/). 
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5 Clinical effectiveness 
5.1 Outcomes 
The following outcomes were defined as crucial to derive a recommendation 
concerning the preventive use of e-TNS: 
 Reduction in monthly migraine days 
 Reduction in monthly acute antimigraine drug intake 
 Satisfaction 
The following outcomes were defined as crucial to derive a recommendation 
concerning the acute treatment use of e-TNS: 
 Change in pain score units on VAS scale compared to baseline  
at 1/2/24 hours 
 Patients on acute antimigraine medication at 2/24 hours 
 Satisfaction 
Further outcomes concerning the preventive use of e-TNS considered were: 
 Reduction in monthly migraine attacks 
 Reduction in monthly headache days 
 Responder rate 
 QoL 
 Compliance 
Further outcomes concerning the acute treatment use of e-TNS  
considered were: 
 Headache pain free patients at 2/24 hours post treatment 
 Improvement in nausea, vomiting, sensitivity to light and sound  
at 2 hours 
 QoL 
 Compliance 
The outcome of Reduction in monthly migraine days was chosen as crucial 
to derive a recommendation concerning the preventive use of e-TNS because 
it is understood to capture best the impact of the diagnosis of migraine on 
the patient. Compared to Reduction in monthly migraine attacks, the pa-
tient can experience more migraine days as a result of a single migraine at-
tack and compared to Reduction in monthly headache days, headache is un-
derstood as only one migraine symptom among a variety of others. Also, 
the ICHD-3 diagnostic criteria distinguish between episodic and chronic mi-
graine precisely on the basis of the number of migraine days per month [2]. 
Responder rate refers to the number of patients with a 50% or greater reduc-
tion in frequency of migraine days at the end of the study vs. the baseline. 
The authors agreed to include responder rate with regard to migraine days 
as an outcome, as the number of migraine days had been chosen as a crucial 
outcome. 
Reduction of monthly acute antimigraine drug intake measures one of the 
preventive goals of e-TNS, which is the reduction of the use of pharmacolog-
ical interventions that may cause medication overuse headache. 
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Satisfaction was measured in both preventive as well as acute treatment use of 
e-TNS. It was defined as the percentage of patients who were satisfied with 
the treatment (on the scale of very-moderately-not at all) [9] and/or expressed 
the desire to continue with the treatment [11, 13].  
Change in pain score units on VAS scale compared to baseline at 1/2/24 hours 
concerns the acute treatment with e-TNS. The outcome measures patients’ ex-
perience of pain intensity during the migraine attack and after 1/2/24 hours 
post e-TNS acute treatment using an eleven-point visual analogue scale (VAS) 
(from 0 no pain to 10 maximum pain) [14]. Concerning the minimum clini-
cally important difference (MCID) on the VAS, a systematic review con-
cludes that the threshold lies between 0.8 and 4 points (cm of improve-
ment measured on the VAS scale) [16]. Further studies suggest that the 
threshold of MCID in emergency department patients was 1.2 points [30]. 
Headache pain free patients at 2/24 hours concerns the acute e-TNS treat-
ment and it refers to the percentage of patients having a reduction from base-
line headache during a migraine attack to no headache at 2/24 hours [15]. 
Patients on acute antimigraine medication at 2/24 hours concerns the acute 
treatment with e-TNS. It measures the need of patients to take acute antimi-
graine medication at 2/24 hours post e-TNS acute treatment [14]. 
Concerning prevention, compliance was assessed by a built-in electronic sys-
tem in the e-TNS device that recorded the use of e-TNS stimulators by each 
patient [12]. Concerning acute treatment, compliance was defined as withdraw-
al, loss to follow-up, or violation of protocol [15]. 
Improvement in nausea, vomiting, sensitivity to light and sound at 2 hours 
concerns the acute e-TNS treatment and it refers to the improvement in most 
bothersome migraine symptoms. It captures the percentage of patients with 
an improvement in nausea, vomiting, sensitivity to light and sound at 2 hours 
after the beginning of the e-TNS session [15]. 
 
 
5.2 Included studies 
For the assessment of clinical effectiveness, two studies met the inclusion cri-
teria. One randomized controlled trial (RCT) for the preventive use of e-TNS 
[9] and one RCT for the acute treatment use of e-TNS [10]. Both compared 
the e-TNS (Cefaly®) to a sham (Cefaly®) device. The latter was not in the form 
of a peer-reviewed publication, but in the form of a study protocol and study 
results published at clinicaltrials.gov [10].  
Study characteristics 
Both RCTs were conducted in multiple centres, were double-blind, and were 
conducted in Belgium [9] and the US [10]. The studies were sponsored by 
the manufacturer STX Med – Cefaly® Technology or by the Walloon Region 
(where the manufacturer provided the e-TNS devices). In the preventive study, 
the length of follow-up was 90 days [9], while in the acute treatment study, 
the follow-up was 24 hours [10]. 
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In the preventive RCT [9], the e-TNS device had a pulse frequency of 60 Hz, 
pulse width of 250 μs, and maximum intensity 16 mA. The comparator had 
the pulse frequency of 1 Hz, pulse width 30 μs, and maximum intensity 1 mA. 
Both were used for 20 minutes long sessions per day [9]. In the acute treat-
ment RCT [10], the e-TNS device had a pulse frequency of 100 Hz, a pulse 
width of 250 μs, and a maximum intensity of 16 mA. The comparator had 
pulse frequency of 3 Hz and a pulse width of 250 μs. Both were used as 60 
minutes long interventions [10]. See Table 5-1. 
Table 5-1: Technical characteristic of the e-TNS (Cefaly®) devices 
 Preventive e-TNS 
device [9, 11-13] 
Preventive e-TNS 
sham device [9] 
Acute treatment e-TNS 
device [10, 14, 15] 
Acute treatment e-
TNS sham device [10] 
Pulse frequency 60 Hz 1 Hz 100 Hz 3 Hz 
Pulse width 250 μs 30 μs 250 μs 250 μs 
Maximum intensity 16 mA 1 mA 16 mA NA 
Length of treatment 20 min/day 20 min/day 60 – 120 min 60 min 
 
Patient characteristics  
Schoenen et al. included 67 patients, of which 34 were in the intervention group 
(IG) and 33 in the control group (CG) and 91% were women [9]. Of the 67 
patients, eight (11.9%) were lost to follow-up. Chou et al. included 106 pa-
tients, of which 52 were in the IG and 54 in the CG and 86.8% were women 
[10]. Of the 106 patients, five (9.6%) of IG patients and two (3.7%) of the CG 
patients were lost to follow-up. The mean age of patients was similar in both 
studies and ranged between 34.59 and 40.09. 
In terms of the differences between inclusion and exclusion criteria between 
the two RCTs [9, 10], Schoenen et al. included only EM patients [9], while 
Chou et al. included both EM and CM patients [10]. Chou et al. required the 
migraine attack to last at least for 3 hours, have pain intensity stabilized for 
1 hour, and have the headache located in the frontal-retro-peri-orbital area 
[10]. Schoenen et al. further excluded patients who had preventive antimi-
graine treatment three months prior, in whom more than three antimigraine 
medications failed, who had medication overuse headache, frequent/chronic 
tension type headache, or severe neurologic or psychiatric disorders [9]. Chou 
et al. excluded patients who were pregnant, who had Botox or supra-orbital 
nerve blocks in the past four months, who had other primary/secondary head-
ache (except medication overuse), temporal/occipital headache, or compli-
cated migraine (hemiphlegic, basilar-type, ophthalmoplegic, migranous in-
farction). Furthermore, they excluded patients who used opioid medication, 
migraine abortive medications in past three hours, or who had allodynia (over-
sensitivity to pain), metal or electric implants in head, cardiac pacemaker, 
implantable cardioverter defibrillator (ICD), or wearable cardioverter defib-
rillator (WCD) or who previously used a Cefaly® device. 
Study characteristics and results of included studies are displayed in Table 
A-1 to A-4 and in the evidence profile in Tables 7-1 and 7-2. 
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5.3 Results 
Mortality 
D0001 – What is the expected beneficial effect of e-TNS on mortality? 
D0003 – What is the effect of e-TNS on the mortality due to causes  
other than episodic/chronic migraine? 
No evidence was found to answer the research questions. None of the includ-
ed studies reported cases of overall or disease-specific mortality, neither in 
the acute treatment nor the sham group. 
 
Morbidity 
D0005 – How does e-TNS affect symptoms and findings (severity, 
frequency) of episodic/chronic migraine? 
Prevention 
In terms of the preventive effect of e-TNS, the symptoms of migraine attacks, 
headache days, and migraine days (and responder rate of >50% reduction in 
migraine days) were measured. 
In EM, patients in the IG had a mean reduction in monthly migraine attacks 
of 0.82 days, while patients in the CG of 0.15 days. The difference (net gain 
in the IG) was 0.67 days (p=0.044) [9]. 
With respect to headache days, patients in the IG had a mean reduction of 
2.51 days, while patients in the CG of 0.23 days. The difference (net gain in 
the IG) was 2.28 day (p = 0.041) [9]. 
With respect to migraine days, patients in the IG had a mean reduction of 
2.06 days, while patients in the CG of 0.32 days. The difference (net gain in 
the IG) was 1,74 days (p = 0.054) [9]. 
The responder rate, the number of patients with a 50% or greater reduction 
in frequency of migraine days at the end of the study vs. the baseline, was 
40% (12 patients) in the IG as opposed to 13.8% (4 patients) in the CG [9]. 
For further details, see Table A-1. 
Acute treatment 
In terms of the acute treatment effect of e-TNS during the migraine attack, 
the intensity of pain was measured on a VAS scale (0 (no pain) to 10 (maxi-
mum pain)), at 1/2/24 hours post-acute treatment. 
In both EM and CM, patients in the IG had a mean reduction of 3.46 points 
(SD=2.32) at one hour post intervention, while patients in the CG of 1.78 
points (SD=1.89). The difference (net gain in the IG) was 1.68 points (p= 
0.0001) [10]. 
At two hours post intervention, patients in the IG had a mean reduction of 
2.87 points (SD=2.24), while patients in the CG of 1.85 points (SD=1.96). 
The difference (net gain in the IG) was 1.02 points (p=0.028) [10]. 
 
keine Evidenz zur 
gesamten oder 
krankheitsspezifischen 
Mortalität 
präventive Anwendung 
von e-TNS: 
signifikant weniger 
Migräneattacken/Monat 
in IG 
 
signifikant weniger 
Kopfschmerztage in IG 
weniger Migränetage in 
der IG, nicht statistisch 
signifikant bei 5 %  
höhere Responderrate  
in der IG 
akute Anwendung  
von e-TNS: 
signifikante 
Verbesserung der 
Schmerzintensität in IG 
(+1,68 Punkte) nach 1h 
signifikante 
Verbesserung der 
Schmerzintensität in IG 
(+1,02 Punkte) nach 2h 
Clinical effectiveness 
LBI-HTA | 2018 35 
At 24 hours post intervention, patients in the IG had a mean reduction of 
3.46 points (SD=2.65), while patients in the CG of 2.38 points (SD=2.27). 
The difference (net gain in the IG) was 1.08 points (p=0.062) [10]. For fur-
ther details, see Table A-1. 
D0006 – How does e-TNS affect progression (or recurrence)  
of episodic/chronic migraine? 
Because the use of antimigraine medication is associated with side effects, 
namely with MOH, because patients can be refractory to antimigraine medi-
cation, and because episodic migraine can naturally progress into chronic 
migraine [1], which can lead to additional antimigraine drug intake, the out-
come of acute antimigraine drug intake is reported here. 
Prevention 
In terms of the preventive use of e-TNS in EM, patients in the IG had a mean 
reduction in monthly acute antimigraine drug intake of 4.2 instances (de-
crease from 11.45 (SD=8.35) at baseline to 7.25 (SD=7.31) at 90 days follow-
up with p = 0.0057). Patients in the CG had an increase of 0.04 instances 
(increase from 9.24 (SD=4.75) to 9.28 (SD=5.69) with p=0.822). The differ-
ence (net gain in the IG) was 4.24 instances (p=0.0072) [9].  
Acute treatment 
In terms of the acute treatment use of e-TNS in EM and CM, there were three 
patients (5.8%) in the IG on acute antimigraine medication at two hours post 
intervention, while in the CG, there were two (3.7%). The difference (net loss 
in the IG) was 1 patient (p=0.666) [10]. 
At 24 hours post intervention, there were 18 patients in the IG (34.6%) on 
acute antimigraine medication, while in the CG, there were 21 patients (38.9%). 
The difference (net gain in the IG) was 3 patients (3.3%) (p=1) [10]. 
 
Function 
D0011 – What is the effect of e-TNS on patients’ body functions? 
The effect of e-TNS on patients’ body functions is associated with arousal 
changes and skin issues. The use of e-TNS is correlated to the experience of 
sleepiness, fatigue, or insomnia [17, 31]. It is further associated with paraes-
thesia (tingling, tickling, pricking, numbness or burning of a person's skin) 
and local skin allergy [17]. 
D0016 – How does the use of e-TNS affect activities of daily living? 
The preventive use of e-TNS requires the patient to spend 20 minutes per day 
performing the stimulation. The acute treatment use is only applied during 
the attack as a 60-120 minutes long intervention. 
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Health-related quality of life 
D0012 – What is the effect of e-TNS on generic  
health-related quality of life? 
D0013 – What is the effect of e-TNS on disease-specific quality of life? 
No evidence was found to answer the research questions. None of the included 
studies reported QoL, neither in the preventive/acute treatment nor the sham 
groups. 
 
Patient satisfaction 
D0017 – Was the use of e-TNS worthwhile? 
Patient satisfaction was only reported in the preventive study in Schoenen et 
al. where 70.6% (IG) as opposed to 39.4% (CG) of patients reported moder-
ate to high satisfaction (31.2% difference) [9].  
 
 
keine Evidenz zur 
Beantwortung der Frage 
e-TNS für Prävention: 
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6 Safety 
6.1 Outcomes 
The following outcomes were defined as crucial to derive a recommendation: 
 SADEs 
Further outcomes considered were: 
 Pain/intolerance to paraesthesia (burning sensation) 
 Arousal changes (insomnia, sleepiness/fatigue) 
 Headaches after stimulation 
 Skin allergy 
 Neck tension 
 Nausea after stimulation  
 Dizziness 
 Vomiting 
 Pain in the jaw 
 Discomfort in teeth 
 Pain in eyes 
 Cold feet 
The serious adverse events associated with the preventive as well as acute 
treatment use of e-TNS are considered crucial.  
 
 
6.2 Included Studies 
For the assessment of safety, seven studies met the inclusion criteria. Two RCTs 
are described in the section on clinical effectiveness above [9, 10]. Further 
five prospective case series that met the inclusion criteria for assessing safety 
will be described below. One of the five case series publications was not in 
the form of a peer-reviewed publication, but in the form of a study protocol 
and study results published at clinicaltrials.gov [15]. 
Study characteristics 
Two case series were conducted in more than one centre [11, 13] and the re-
maining three were single centre studies [12, 14, 15]. Three were sponsored 
by STX Med – Cefaly® Technology and were conducted in the US and Greece. 
In the remaining two case series studies from Italy, the source of funding was 
unclear, but it was stated that the devices were provided by the manufacturer 
[11, 12]. 
In the preventive case series studies, the length of follow-up ranged from 60 
to 120 days [11-13], while in the acute treatment case series studies, the fol-
low-up was 24 hours post treatment [14, 15]. 
The devices used for the preventive as well as acute treatment use of e-TNS are 
the same as outlined in Table 5-1. One study did not indicate the device type 
[13]. 
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Patient characteristics 
The three preventive case series studies included 24, 23, and 37 patients, re-
spectively [11-13]. Hence, together with the preventive RCT [9], the total num-
ber of patients receiving e-TNS for the prevention of migraine attacks was 118. 
Together with the CG, out of the 151 patients, 75-91% were women and a to-
tal of 24 patients was lost to follow-up. The mean age varied between 32.9 to 
45 years. The two acute treatment case series studies included 35 and 60 pa-
tients, respectively [14, 15]. Hence, together with the acute treatment RCT [10], 
the total number of patients receiving e-TNS for the acute treatment of mi-
graine attacks was 147. Together with the CG, out of the 201 patients, 80-
89.6% were women and a total of 24 patients were lost to follow-up. The me-
an age varied between 39.4 to 46.9 years. 
In terms of the differences between inclusion criteria in the preventive use of 
e-TNS, the main difference is that Russo et al. and Schoenen et al. only in-
clude EM patients [9, 12], while DiFiore et al. include only CM patients for 
more than one year [11], and Vikelis et al. both EM and CM patients [13]. 
DiFiore et al. further include patients both with and without MOH [11], but 
Schoenen et al. exclude them [9], and Vikelis et al. include patients refracto-
ry/intolerant to Topiramate [13]. Exclusion criteria are either not explicit, 
or they differ. Russo et al. exclude patients with other types of headache, pa-
tients on daily medication intake, migraine drug-naïve patients, and patients 
without structural brain abnormalities [12]. DiFiore et al. exclude pregnant 
patients and patients with major neurological, systemic, or psychiatric illness-
es [11]. 
In terms of the differences between inclusion criteria in the acute treatment 
use of e-TNS, the main difference is that Chou et al. include both EM and 
CM patients [10, 14], while Mann only includes EM patients [15]. Mann fur-
thermore only includes those patients, who had their migraine onset before 
50 years of age and who have had 2-8 moderate to severe attacks per month 
in the prior two months [15]. Chou et al. further include patients whose at-
tack has lasted for more than three hours, their pain intensity was stabilized 
for an hour, or those patients who have had a frontal-retro-peri-orbital head-
ache [10, 14]. 
Both Chou et al. and Mann exclude patients with Botox in the head and su-
pra-orbital nerve blocks in past four months, patients with other primary or 
secondary headache (except MOH), patients using opioid medication, or pa-
tients with metal/electric implants in the head, cardiac pacemaker, ICD, and 
WCD patients. On top of that, Mann excludes patients with migraine aura 
without headache, brainstem aura migraine, or patients with migraine pro-
phylaxis modification in prior three months, and patient who abuse alcohol/ 
illicit drugs [15]. Chou et al. exclude pregnant patients, temporal/occipital 
headache patients, or patients who used abortive medication in past three 
hours, who are oversensitive to pain, or who have a complicated migraine di-
agnosis [10, 14]. 
Study characteristics and results of included studies are displayed in Table 
A-1 to A-4 and in the evidence profile in Tables 7-1 and 7-2. 
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6.3 Results 
Patient safety 
C0008 – How safe is e-TNS in comparison to the comparator(s)? 
Prevention 
No SADE’s occurred in the preventive studies. 
In terms of ADEs, two studies reported that there were none [9, 12], while 
intolerance to paraesthesia (burning sensation) was reported in 34.3% of pa-
tient in [13]. Furthermore, headache after stimulation as well as neck tension 
were reported in one study [11], where headache occurred in 8.7% of patients, 
while neck tension in 4.3%. 
In one study, 10.8% of patients experienced technical issues with the e-TNS 
device [13]. 
Acute treatment 
No SADEs occurred in acute treatment studies.  
In terms of ADEs, one study reported that there were none [14]. Intolerance 
to paraesthesia was documented in two acute treatment studies in 5.8% (IG 
n=52) vs. 1.9% (CG n=54) [10] and 11.9% of patients [15]. Nausea after 
stimulation was reported in two studies in 1.9% (IG n=52) vs. 0% (CG n=54) 
[10] and 3.5% of patients [15].  
Furthermore, arousal changes (insomnia, sleepiness/fatigue, drowsiness), diz-
ziness, vomiting, pain in the jaw, discomfort in teeth, pain in eyes, and cold 
feet occurred in one study all in 1.7% of patients [15]. In the same study, 
18.3% of patients reported skin allergy/irritation. 
C0002 – Are the harms related to dosage or frequency of applying e-TNS? 
No relationship between dosage and frequency of applying e-TNS was found. 
The only point of concern is the increase in ADEs in Mann, where the high-
er acute treatment pulse frequency of 100 Hz was applied [15]. An increased 
number of ADEs was, however, not confirmed in the other two acute treat-
ment studies with the same pulse frequency [10, 14]. 
C0004 – How does the frequency or severity of harms change  
over time or in different settings? 
Due to the short length of follow-up, there is no data to answer this question. 
C0005 – What are the susceptible patient groups that are more likely  
to be harmed through the use of e-TNS? 
C0007 – Are e-TNS and comparator(s) associated with  
user-dependent harms 
The patient groups that are most susceptible to be harmed by e-TNS are those 
patients who can be influenced by the ADEs present. Those are patients who 
can be unduly influenced by fatigue and the related lack of attention such as 
car drivers. Also, patients who have mental or physical difficulty operating a 
device that used electric impulses or patients in whom the allergic reaction 
to the electrode on their forehead may cause personal or professional chal-
lenges such as first point of personal contact people. 
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Investments and tools required 
B0010 – What kind of data/records and/or registry is needed  
to monitor the use of e-TNS and the comparator(s)? 
Larger RCTs and prospective registry data are needed to monitor the use of 
e–TNS and thus provide a longer follow-up data. 
 
 
größere RCTs und pros-
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mit längerer 
Nachbeobachtungszeit 
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7 Quality of evidence 
The risk of bias (RoB) for individual studies was assessed with the Cochrane 
Collaboration’s tool for randomised trials [32] as well as with the Institute of 
Health Economics (IHE) checklist for single-arm studies [33]. Both assess-
ments are presented in Tables A-5 and A-6 in the Appendix. The preventive 
RCT [9] was rated with a moderate RoB, whereas the acute treatment RCT 
[10] was rated with a high RoB. In both cases it was unclear whether the 
randomization sequence was adequate. Furthermore, in the acute treatment 
RCT [10], the method of concealment was not described to allow a definite 
judgement. Selective outcome reporting was unclear in both studies as it was 
assumed that not all ADEs were reported. Also, there was a conflict of inter-
ests present in the acute treatment study [10] as it was funded by the manu-
facturer. 
In the prospective case series studies used for the assessment of safety, one 
study was rated with low RoB [12], three studies were rated as moderate [11, 
14, 15], and one study was rated with high RoB [13]. The reasons for down-
grading were mainly non-consecutive selection of patients, lack of clarity con-
cerning the reporting on co-interventions, lack of blinding, lack of the use of 
parametric statistics, and lack of reporting of the sources of funding.  
The strength of evidence was rated according to GRADE (Grading of Rec-
ommendations Assessment, Development and Evaluation) Schema [36] for 
each endpoint individually. Each study was rated by three independent re-
searchers. A more detailed list of criteria applied can be found in the rec-
ommendations of the GRADE Working Group [36]. 
GRADE uses four categories to rank the strength of evidence: 
 High = We are very confident that the true effect lies close to that of 
the estimate of the effect;  
 Moderate = We are moderately confident in the effect estimate: the 
true effect is likely to be close to the estimate of the effect, but there 
is a possibility that it is substantially different;  
 Low = Our confidence in the effect estimate is limited: the true effect 
may be substantially different from the estimate of the effect;  
 Very low = Evidence either is unavailable or does not permit  
a conclusion. 
The ranking according to the GRADE scheme for the research question can 
be found in Table 7-1. 
Overall the strength of evidence for the effectiveness and safety of e-TNS for 
prevention in comparison to the sham e-TNS device is low and very low in 
outcomes of satisfaction, ADEs, and SADEs. Concerning acute treatment, the 
strength of evidence is very low overall. 
For the comparison of e-TNS with the standard practice comparators such 
as triptans, NSAIDs/paracetamol for acute treatment, and propranolol and 
topiramate for prevention, no evidence was found. 
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Table 7-1: Summery of findings table: efficacy and safety of e-TNS for the prevention of episodic/chronic migraine patients 
Outcomes Anticipated absolute effects* (97.5% CI) Relative effect 
(97.5% CI) 
№ of participants  
(studies) 
Certainty of  
the evidence 
(GRADE) 
Comments 
Reduction in monthly migraine attacks 
assessed with: mean number of days 
The mean reduction in the number of monthly 
migraine attacks in the IG was 0.67 more. 
- 67 
(1 RCT) 
⨁⨁◯◯ 
LOW a)b) 
Statistically significant  
(p = 0.044) 
Reduction in monthly migraine days 
assessed with: mean 
The mean reduction in the number of monthly 
migraine days in the IG was 1.74 more. 
- 67 
(1 RCT) 
⨁⨁◯◯ 
LOW a)b) 
Statistically not 
significant (p = 0.054) 
Reduction of monthly headache days 
assessed with: mean 
The mean reduction in the number of monthly 
headache days in the IG was 2.28 more. 
- 67 
(1 RCT) 
⨁⨁◯◯ 
LOW a)b) 
Statistically significant  
(p = 0.041) 
Reduction in the number of monthly 
acute antimigraine drug intake 
The mean reduction in the number of monthly acute 
antimigraine drug intake in the IG was 4.24 more. 
- 67 
(1 RCT) 
⨁⨁◯◯ 
LOW a)b) 
Statistically significant  
(p = 0.0072) 
High or moderate Satisfaction 70.6% (IG, n=34) vs.39.4% (CG, n=33) - 67 
(1 RCT) 
⨁◯◯◯ 
VERY LOW a)b) 
Patient reported 
outcome 
Serious Adverse Events 0/34 (IG) vs. 0/33 (CG) - 67 
(1 RCT) 
⨁◯◯◯ 
VERY LOW a)b) 
- 
Adverse Events 0/34 (IG) vs. 0/33 (CG) - 67 
(1 RCT) 
⨁◯◯◯ 
VERY LOW a)b) 
- 
 
* The risk in the IG (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). 
Abbreviations: CG = Control group, CI = Confidence interval, IG = Interventional group, n= number, pts = Patients, RCT = Randomised controlled trial, VAS = Visual Analogue Scale 
Explanations: a) Wrong comparator, b) Small sample size 
Nomenclature for GRADE table:  
Limitations: 0: no limitations or no serious limitations; -1: serious limitations  
Inconsistency: NA: Not applicable (only one trial); 0: no important inconsistency; -1: important inconsistency  
Indirectness: 0: direct, no uncertainty, -1: some uncertainty, -2 major uncertainty  
Other modifying factors: publication bias likely (-1), imprecise data (-1), strong or very strong association (+1 or +2), dose-response gradient (+1), Plausible confounding (+1)  
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Table 7-2: Summary of findings table: efficacy and safety of e-TNS for the acute treatment of episodic/chronic migraine patients 
Outcomes Anticipated absolute effects* (97.5% CI) 
Relative 
effect 
(97.5% CI) 
№ of participants  
(studies) 
Certainty of  
the evidence 
(GRADE) 
Comments 
Reduction in pain score units on VAS scale 
compared to baseline at 1 hr follow up 
The mean improvement in reduction in pain score units 
on VAS scale compared to baseline at 1 hr was 1.68. 
- 106 
(1 RCT) 
⨁◯◯◯ 
VERY LOWa)b)c)d)e) Statistically significant (pGroup = 0.0001) 
Reduction in pain score units on VAS scale 
compared to baseline at 2 hr follow up 
The mean improvement in reduction in pain score units 
on VAS scale compared to baseline at 2 hr was 1.02. 
- 106 
(1 RCT) 
⨁◯◯◯ 
VERY LOW a)b)c)d)e) Statistically significant (pGroup = 0.028) 
Reduction in pain score units on scale 
compared to baseline at 24 hrs 
The mean improvement in reduction in pain score units 
on VAS scale compared to baseline at 24 hrs was 1.08. 
- 106 
(1 RCT) 
⨁◯◯◯ 
VERY LOW a)b)c)d)e) Statistically not significant  
(pGroup = 0.062) 
Patients on acute medication  
at 2 hrs follow up 
3/52(IG) vs. 2/54 (CG) - 106 
(1 RCT) 
⨁◯◯◯ 
VERY LOW a)b)c)d)e) - 
Patients on acute medication at 24 hrs 18/52 (IG) vs. 21/54 (CG) - 106 
(1 RCT) 
⨁◯◯◯ 
VERY LOW a)b)c)d)e) - 
Serious Adverse Events: follow-up 1 day 0/52 (IG) vs. 0/54 (CG) - 106 
(1 RCT) 
⨁◯◯◯ 
VERY LOW a)b)c)d)e) - 
Adverse Events: follow-up 1 day Intolerance to paresthesia in 3/52 (IG) vs. 1/54(CG) pts 
Nausea after stimulation in 1/52 (IG) vs. 0/54 (CG) pts 
- 106 
(1 RCT) 
⨁◯◯◯ 
VERY LOW a)b)c)d)e) - 
 
* The risk in the IG (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). 
Abbreviations: CG = Control group, CI = Confidence interval, hr = hour, IG = Interventional group, n= number, pts = Patients, RCT = Randomised controlled trial, VAS = visual analogue scale 
Explanations: a) Funded by the manufacturer b) Insufficient information about sequence generation process c) Method of concealment in not described to allow definitive judgment d) Wrong comparator e) 
Small sample size 
Nomenclature for GRADE table:  
Limitations: 0: no limitations or no serious limitations; -1: serious limitations  
Inconsistency: NA: Not applicable (only one trial); 0: no important inconsistency; -1: important inconsistency  
Indirectness: 0: direct, no uncertainty, -1: some uncertainty, -2 major uncertainty  
Other modifying factors: publication bias likely (-1), imprecise data (-1), strong or very strong association (+1 or +2), dose-response gradient (+1), Plausible confounding (+1)  
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8 Discussion 
To our knowledge, this is the first systematic review on the preventive and 
acute treatment use of e-TNS in episodic (EM) as well as chronic migraine 
(CM) patients.  
Summary of evidence from prospective clinical studies 
We included two RCTs for the analysis of clinical effectiveness: 
 1 RCT with 67 patients for prevention, of which 34 received  
the e-TNS intervention and  
 1 RCT with 106 patients for acute treatment, of which 52 received  
the e-TNS intervention, and 
additional five prospective case series complementing the analysis of safety: 
 84 preventive patients and 95 acute patients receiving  
the e-TNS intervention. 
Concerning prevention, the results from the RCT (34 e-TNS patients) show 
statistically significant differences between e-TNS and sham treatment in EM 
patients with respect to reduction of migraine attacks (0.67 less migraine at-
tacks per month), migraine days (1.74 less migraine days per month), re-
sponder rate (26.2% more response to treatment), headache days (2.28 less 
headache days per month), acute antimigraine drug intake (4.24 less instanc-
es of acute drug intake per month), and satisfaction (31.2% difference in sat-
isfaction with the CG).  
Concerning acute treatment, the RCT (52 patients) shows statistically signifi-
cant differences between e-TNS and sham treatment suggesting more im-
provement in pain reduction than sham on a VAS scale (out of 11 points) at 
1/2/24 hours post-acute treatment (1.68/1.02/1.08 improvement, respectively).  
The size of the difference measured on VAS scale, however, is of questiona-
ble clinical relevance as concerning the MCID, the results oscillate around 
the lower end of the clinically meaningful benefit threshold [16]. There was 
also an increase of one IG patient in acute antimigraine drug intake at two 
hours post-acute treatment compared to CG, but a decrease of three IG pa-
tients compared to CG at 24 hours. 
Concerning safety, no SADEs occured neither in the RCTs nor in the case 
series. The reporting of AEDs, however, remains to be a point of concern as 
the largest treatment case series study with 60 patients reports several AED’s 
that are unreported in all the remaining studies (dizziness, vomiting, pain in 
the jaw, discomfort in teeth, and pain in eyes). Each occurred only in 1/60 
patients. 
Efficacy data from the three preventive prospective case series suggest a bet-
ter efficacy profile than the preventive RCT [9], namely that e-TNS reduced 
the number of monthly migraine attacks by 2.5 instances [12], monthly mi-
graine days by 3.5 days [12] and by 31% [11], and monthly headache days by 
two days [13]. Also, responder rate in migraine days was 75% in one study 
[12]. Furthermore, monthly acute antimigraine drug intake was reduced by 
40.7%, 49.6%, and 46.3%, respectively [11-13]. In terms of satisfaction, 83.3% 
[12] and 65.7% [13] of patients were satisfied. Furthermore, a survey with 
2,313 EM patients who used e-TNS concludes that 54.4% were satisfied and 
thus were willing to continue the e-TNS treatment [17].  
vorliegende Evidenz: 
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Efficacy data from the two acute treatment prospective case series also suggest 
a better efficacy profile than the acute treatment RCT, namely that 35.4%/ 25% 
of patients were headache pain free at 2/24 hours post-acute treatment, respec-
tively, and 36.7% were free from nausea, vomiting, and sensitivity to light and 
sound at 2 hours [15]. On the VAS scale, there was a 3.22/2.98 decrease of 
pain at 1/2 hours, respectively [14], and 34.6% and 50% of patients were on 
acute medication at 24 hours post-acute treatment, respectively [14, 15]. 
Internal and external validity  
Concerning the effectiveness (RCTs) of prevention and acute treatment with e-
TNS, the quality of evidence was low to very low. The main reasons were the 
small sample size, uncertainty about sufficient reporting of AEDs, and the 
wrong comparator. Concerning safety, the quality of evidence ranged from 
high, moderate, to low and very low (see ROB Tables A-5 and A-6). Further-
more, two studies (case-series) were judged to have a high risk of confound-
ing as co-interventions were either not clearly described [13], or it was clear-
ly stated that preventive as well as acute treatments for chronic migraine were 
not changed during the study [11]. 
Challenges with interpreting the data arise when in the acute treatment use of 
e-TNS, Mann outlines the baseline most bothersome migraine symptoms 
(nausea, vomiting, sensitivity to light and sound) [15], but these baseline 
symptoms are not outlined in the remaining two acute treatment studies, thus 
undermining their internal validity [10, 14]. Furthermore, the role of patients’ 
reports is key in the assessment of antimigraine treatments, yet it is subject 
to a high level of subjectivity as seen on the exclusion criteria in Mann, where 
patients were excluded upon having difficulty distinguishing migraine attacks 
from tension-type headaches [15]. 
In terms of external validity, the data is considered generalizable to other 
contexts. The studies were conducted in Belgium, Italy, Greece, and the US, 
and these contexts are similar to the Austrian one. At the same time, however, 
the differences between inclusion and exclusion criteria undermine the gen-
eralizability. The prevention studies represent the real clinical context, as the 
patients used the e-TNS in their homes, but the acute treatment studies were 
conducted in the hospital setting, yet the e-TNS should be used in the home 
setting for acute treatment as well. 
Compliance is considered to be one of the key issues. In the preventive stud-
ies, compliance ranged in the case series from 81.8% to 83.3% [11-13], and 
in the preventive RCT [9], it was 61.7% (IG) vs. 54.4% (CG). It was not re-
ported in the acute treatment RCT [14], but in the acute treatment case series 
of Mann, it was 82.7% [15]. In the survey with 2,313 patients, 46.6% of pa-
tients were unsatisfied who, in terms of compliance, used the device for the 
recommended period of time only in 48.6% of cases [17]. The real-life com-
pliance with e-TNS is put into question because the relatively high case se-
ries compliance data are contrasted with lower RCT and survey data. 
Also, there is a disproportion in the presence of the female population in the 
studies as 75-91% of the whole patient population were women and 9-25% 
were men. However, the epidemiologic data suggest that EM and CM is only 
three times more prevalent in women than in men [1]. 
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In all studies included in the analysis (except for one, where drug refractory 
patients are included [13]), the alternative treatment option to e-TNS is drug 
therapy. Other non-invasive neuromodulation techniques (TMS, DCS, VNS), 
which are recommended as additional or alternative to drug therapy [23], aim 
at a similar target population in which drug therapy may be replaced [1]. In 
terms of invasive neuromodulation techniques (ONS), chronic refractory pa-
tients are the target population [34].  
Given the small size of the selective sample of patients included in the evi-
dence base (as compared to the large burden of disease that migraine creates), 
the conclusions about effectiveness and the positive safety profile are consid-
ered to be inflated. Larger controlled trials with best practice interventions 
as comparators are necessary for potentially considering e-TNS to be part of 
the standard practice. 
Limitations of evidence 
The evidence base found was only partly relevant in answering the research 
question. Both RCTs identified were relevant for excluding placebo effects, 
but RCT comparing e-TNS to best practice interventions (such as proprano-
lol and topiramate for prevention, and triptans, NSAIDs/paracetamol for acute 
treatment) should be used as comparators. The reason being that the target 
population of e-TNS are not only patients refractory to medication, but also 
drug responsive patients, which makes e-TNS aim to replace the use of med-
ication. That is why a controlled trial comparing e-TNS to either of the above 
outlined (preventive or acute) treatments is necessary. 
Furthermore, outcomes measured in the studies were judged to be relevant 
to patient’s experience, but a standardized evaluation of satisfaction was lack-
ing (especially in the RCTs). It is important to note, however, that the pa-
tient relevant endpoint of QoL was not measured or reported in any of the 
studies. Also, in most acute treatment studies with medication, patients are 
followed for 48 hours for the purpose of measuring headache recurrence. For 
that reason, the follow-up of 24 hours that is applied to all three acute treat-
ment studies is considered to be too short [10, 14, 15]. Also, consistency of the 
effect of e-TNS is undermined because in medication studies, several attacks 
must be treated in one person to prove that the acute therapy works and that 
was not the case. 
Socio-economic and ethical considerations, conclusion 
When considering socio-economic and ethical aspects of this new interven-
tion e-TNS, the effects have to be reflected over against the principles of be-
neficence, non-maleficence, autonomy, distribute justice, and uncertainty. On 
the one hand, by being applied in the home setting (thus securing patient au-
tonomy and easy access), e-TNS claims to reduce the burden on the in-/out-
patient sector by reducing the pharmacological and other healthcare spend-
ing associated with the use of the current preventive and acute treatment op-
tions for EM and CM patients (freeing of resources an accordingly distribute 
justice). And, if proven to be more effective than the best practice compara-
tors, it may also reduce the economic loss associated with decreased econom-
ic productivity of migraine patients [18]. E-TNS also claims to be associated 
with less side effects than the current pharmacological therapy and thus, it 
may better protect the principles of medical beneficence and patient’s au-
tonomy.  
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On the other hand, however, the lack of clarity behind the mechanism of ac-
tion of e-TNS casts doubts over its positive safety profile [19-21, 35]. This is 
further coupled by the location of the device placed at the patient’s forehead 
as any possible long-term ADEs, not yet measured by the current evidence, 
may be found crucial (with respect to non-maleficence). It is not clear to what 
extent the electrical field applied in such close proximity to the brain for such 
an extended period of time influences the brain. As outlined above, to pre-
vent breaching the principle of non-maleficence, larger controlled trials are 
needed to match the size of the population that e-TNS targets. Currently, 
there is only one ongoing RCT for the acute treatment use of e-TNS that aims 
to recruit 600 patients with an estimated primary completion date of Octo-
ber 2018, however, it lacks the measurement of any longer-term outcomes 
(more than 24 hours) (NCT03465904). 
While e-TNS has the potential to improve patients’ autonomy and reduce the 
total medication intake, its non-invasive nature needs to be put in the con-
text of the paucity of knowledge about its mechanism of action and thus its 
long term safety profile. Furthermore, the potential cost-effectiveness of e-
TNS needs to be contrasted with the small effects measured by the VAS and 
the small sample size included in the studies with the large real life target 
population. 
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9 Recommendation 
In Table 9-1 the scheme for recommendations is displayed and  
the according choice is highlighted. 
Table 9-1: Evidence based recommendations 
 The inclusion in the catalogue of benefits is recommended.  
 The inclusion in the catalogue of benefits is recommended with restrictions. 
X The inclusion in the catalogue of benefits is currently not recommended. 
 The inclusion in the catalogue of benefits is not recommended. 
 
Reasoning: 
The current evidence indicates that the assessed technology e-TNS in epi-
sodic and chronic migraine patients is more effective and equally safe as the 
comparator sham Cefaly® device. The quality of the body of evidence suggest-
ing this is, however, low to very low. Because there is no evidence base that 
would compare e-TNS to best practice standard treatment, new study results 
with standard practice comparators will influence the effect estimate consid-
erably. Also, concerning safety, an RCT with a larger sample size will influ-
ence the safety profile considerably. 
Due to the lack of ongoing studies that could sufficiently broaden the evi-
dence base, no specific date for re-evaluation is recommended. 
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Appendix 
Evidence tables of individual studies included for clinical effectiveness and safety 
Table A-1: e-TNS: Results from randomised controlled trials for prevention of episodic and chronic migraine 
 Schoenen et al. [9] (2013) 
Country Belgium 
Sponsor Walloon Region1 
Study design Multi-centre, prospective, double-blinded, randomised, sham-controlled trial 
Conducted in 09/2009 – 09/2011 
Indication Preventive treatment in pts with episodic migraine with and without aura 
Intervention (I) e-TNS (pulse frequency 60 Hz, pulse width 250 μs, max intensity 16 mA, 20 min/day) 
Comparator (C) Sham Cefaly
®
 device (pulse frequency 1 Hz, pulse width 30 μs, max intensity 1 mA, 20 min/day) 
Number of pts (I vs. C) 34 vs. 33 
Inclusion criteria Pts 18-65 yrs, migraine with or without aura meeting ICHD-II code 1.2.1 or 1.1 criteria, episodic migraine of ≤2 attacks per mo 
Exclusion criteria Preventive antimigraine treatment in prior 3 mos, failure of ≥3 antimigraine medications, medication overuse 
headache, frequent/chronic tension type headache, severe neurologic or psychiatric disorders 
Primary outcome measure Change in monthly migraine days and 50% responder rate 
Secondary outcome measure Change in monthly frequency of any headache, change in mean headache severity per migraine day (4 points scale), 
change in monthly acute antimigraine drug use, percentage of patients stating satisfaction 
Baseline patient characteristics (I vs. C) (intention-to-treat)  
Mean age, yrs (SD) 34.59 (11.01) vs. 39.06 (9.87) 
Sex, female:male, n 31:3 vs. 30:3 
Migraine with aura, n (%) 
Migraine without aura, n (%) 
Migraine duration, yrs (SD) 
Migraine attack duration in hrs, median (IQR) 
Pts on acute medication, n 
10 (29.4) vs. 10 (30.3)2 
24 (70.6) vs. 23 (69.7) 
14.71 (9.39) vs. 18.17 (11.68) 
NA 
NA 
                                                             
1 The manufacturer STX Med provided the Cefaly
®
 devices 
2 While all pts had migraine without aura, 20 pts had occasional visual aura preceding the attack. 
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 Schoenen et al. [9] (2013) 
Follow-up time, days 90 
Loss to follow-up, n (%) 8 (11.9) 
Efficacy 
Reduction in monthly migraine attacks, mean n (SD) 
Difference between I and C 
4.37 (1.87)/3.55 (2.94) with p = 0.058 vs. 4.04 (1.52)/3.89 (1.89) with p = 0.516 (baseline/90 days) 
p = 0.044 
Reduction in monthly migraine days, mean n (SD)  
Difference between I and C 
6.94 (3.04)/4.88 (3.46) with p = 0.023 vs. 6.54 (2.61)/6.22 (2.99) with p = 0.082 (baseline/90 days) 
p = 0.054 
Reduction in monthly headache days, mean n (SD)  
Difference between I and C 
7.78 (4.00)/5.27 (3.55) with p = 0.011 vs. 6.72 (2.63)/6.49 (3.2) with p = 0.674 (baseline/90 days) 
p = 0.041 
Reduction in the number of monthly acute antimigraine  
drug intake, mean n (SD)  
Difference between I and C 
11.45 (8.35)/7.25 (7.31) with p = 0.0057 vs 9.24 (4.75)/9.28 (5.69) with p = 0.822 (baseline/90 days) 
p = 0.0072 
Responder rate, reduction in migraine days, baseline vs. 
follow-up, n (%) 
12 (40) vs. 4 (13.8) 
QoL NA 
Satisfaction, n (%) (very/moderately/not at all satisfied/NA)  29.4 (10)/41.2 (14)/21.2 (7)/8.8 (3) vs. 18.2 (6)/21.2 (7)/51.5 (17)/9.1 (3) 
Compliance, mean n of sessions out of 90 (%) 55.54 (61.7) vs. 49 (54.4) 
Safety 
SADEs , n (%) 
Pain/intolerance to paresthesia (burning sensation), n (%) 
Arousal changes (insomnia, sleepiness/fatigue), n (%) 
Headaches after stimulation, n (%) 
Nausea after stimulation, n (%) 
Skin allergy/irritation , n (%) 
0 
0 
0 
0 
0 
0 
C – comparator, e-TNS – external trigeminal nerve stimulation, ICD – implantable cardioverter defibrillator, ICHD – International Classification of Headache Disorders,  
IHS – International Headache Society, I – intervention, IQR – inter-quartile range, hrs – hours, mos – months, min – minutes, NA – data not available, pts – patients,  
QoL – quality of life, SADEs – serious adverse device effects, SD – standard deviation, yrs – years, VAS – visual analogue scale, WCD – wearable cardioverter defibrillator 
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Table A-2: e-TNS: Results from randomised controlled trials for acute treatment of episodic and chronic migraine 
 Chou et al. [10] (2018) 
Country United States 
Sponsor STX Med – Cefaly
® Technology 
Study design Multi-centre, prospective, double-blinded, randomised, sham-controlled trial (NCT02590939) 
Conducted in 02/2016 – 03/2017 
Indication Acute treatment in pts with acute migraine (episodic or chronic) with or without aura 
Intervention (I) e-TNS (pulse frequency 100 Hz, pulse width 250 μs, max intensity 16 mA, 60 min) 
Comparator (C) Sham Cefaly
®
 device (pulse frequency 3 Hz, pulse width 250 μs, max intensity NA, 60 min) 
Number of pts (I vs. C) 52 vs. 54 
Inclusion criteria Pts 18-65 yrs, episodic/chronic migraine with or without aura meeting ICHD-III criteria, 3 hrs long attack, pain intensity 
stabilized for 1 hr, frontal-retro-peri-orbital headache 
Exclusion criteria Pregnancy, Botox in past 4 mos, supra-orbital nerve blocks in past 4 mos, other primary/secondary headache (except 
medication overuse), temporal/occipital headache pts, opioid medication use, migraine abortive medications in past 3 
hrs, allodynia (oversensitivity to pain), metal or electric implants in head, cardiac pacemaker, ICD, WCD, previous 
Cefaly
®
 pts, pts with complicated migraine (hemiphlegic, basilar-type, ophthalmoplegic, migranous infarction) 
Primary outcome measure Mean change in pain score at 1 hr after intervention 
Secondary outcome measure Mean change in pain score at 2 hrs/24hrs compared to baseline (VAS scale), pts’ used rescue medication after 2/24 hrs 
Baseline patient characteristics (I vs. C) (intention-to-treat)  
Mean age, yrs (SD) 39.71 (13.62) vs. 40.09 (12.65) 
Sex, female:male, n 43:9 vs. 49:5 
Migraine with aura, n (%) 
Migraine without aura, n (%) 
Migraine duration, yrs 
Migraine attack duration in hrs, median (IQR) 
Pts on acute medication, n 
12 (23.1) vs. 5 (9.3) 
40 (76.9) vs. 49 (90.7) 
NA 
7 (4-48) vs. 6 (4.63-20.75) 
17 vs. 14 
Follow-up time, days 1 
Loss to follow-up, n (%) 5 (9.6) vs. 2 (3.7)3 
                                                             
3 In the IG and the CG, 3 and 1 subjects withdrew and 2 and 1 subjects failed nociceptive test, respectively. 
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 Chou et al. [10] (2018) 
Efficacy 
QoL NA 
Satisfaction, n (%)  NA 
Reduction in pain score units on VAS scale compared to 
baseline at 1 hr, mean n (SD) 
-3.46 (2.32); p = 0.0001 vs. -1.78 (1.89); p = 0.0001 
pGroup = 0.0001 
Reduction in pain score units on VAS scale compared to 
baseline at 2 hrs, mean n (SD) 
-2.87 (2.24); p = 0.0001 vs. -1.85 (1.96); p = 0.0001 
pGroup = 0.028 
Reduction in pain score units on VAS scale compared to 
baseline at 24 hrs, mean n (SD) 
-3.46 (2.65); p = 0.0001 vs.-2.38 (2.27); p = 0.0001 
pGroup = 0.062 
Pts on acute antimigraine medication at 2/24 hrs, n (%) 
Difference between I and C 
3 (5.8)/18 (34.6) vs. 2 (3.7)/21 (38.9)4 
0.66/1 
Compliance, mean n of sessions out of 90 (%) NA 
Safety 
SADEs , n (%) 
Pain/intolerance to paresthesia (burning sensation), n (%) 
Arousal changes (insomnia, sleepiness/fatigue), n (%) 
Headaches after stimulation, n (%) 
Nausea after stimulation, n (%) 
Skin allergy/irritation , n (%) 
0 vs. 0 
3 (5.8) vs. 1 (1.9)5 
NA 
NA 
1 (1.9) vs. 0 
NA 
C – comparator, e-TNS – external trigeminal nerve stimulation, ICD – implantable cardioverter defibrillator, ICHD – International Classification of Headache Disorders,  
IHS – International Headache Society, I – intervention, IQR – inter-quartile range, hrs – hours, mos – months, min – minutes, NA – data not available, pts – patients,  
QoL – quality of life, SADEs – serious adverse device effects, SD – standard deviation, yrs – years, VAS – visual analogue scale, WCD – wearable cardioverter defibrillator 
 
  
                                                             
4 The data on the use of rescue medication was not available for 9.6%/13.5% vs. 3.7%/5.6% of pts at 2/24 hrs. 
5 Before completion of the 1 hr of e-TNS session. 
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Table A-3 e-TNS: Results from observational studies for prevention of episodic and chronic migraine 
 Russo et al. [12] (2015) DiFiore et al. [11] (2017) Vikelis et al. [13] (2017) 
Country Italy Italy Greece 
Sponsor unclear6 unclear6 STX Med-Cefaly
®
 Technology and Brain 
Therapeutics Greece 
Study design Prospective single-arm, interventional trial Prospective single-arm, interventional, open label 
preliminary trial 
Multi-centre, prospective, single-arm, 
interventional trial (NCT03125525) 
Conducted in 01/2013 – 10/2014 04/2014 – 12/2014 NA 
Indication Preventive treatment in pts with episodic 
migraine without aura 
Preventive treatment in pts with chronic migraine 
with or without medication overuse 
Preventive treatment in pts with episodic 
or chronic migraine refractory or intolerant 
to Topiramate/Phrophylaxe 
Intervention (I) e-TNS (pulse frequency 60 Hz, pulse width 
250 μs, max intensity 16 mA, 20 min/day) 
e-TNS (pulse frequency 60 Hz, pulse width 250 μs, 
max intensity 16 mA, 20 min/day) 
e-TNS (20 min/day) 
Comparator (C) none none none 
Number of pts (I vs. C) 247 23 378 
Inclusion criteria Migraine without aura meeting  
ICHD-III criteria,  
episodic migraine of ≤5 attacks per mo 
Pts 18+ yrs, chronic migraine with or without 
medication overuse headache+ meeting ICHD-III criteria, 
chronic migraine for 1+ yrs, not part of withdrawal 
program to stop medication overuse, normal 
neurological exam, normal neuroimaging findings 
Pts refractory/intolerant to topiramate, 
episodic/chronic (≥15 days headache/mo) 
migraine according to ICHD-III criteria, 
stop topiramate 3 mos prior 
Exclusion criteria Other type of headache, somatic and 
psychosomatic conditions, daily medication 
intake, migraine drug-naïve pts, no structural 
brain abnormality confirmed by MRI 
Pregnancy, major neurological, systemic or 
psychiatric illness 
NA 
Primary outcome measure Change in monthly migraine days and 
migraine attacks, % of pts having ≥50% 
reduction of monthly migraine attacks and 
migraine days 
50% or more reduction in both headache days per 
month, and in consumption of acute headache relief 
medications per month 
Change in total headache days and days 
with acute medication use 
Secondary outcome measure Average of pain intensity during migraine 
attacks (VAS scale), intake of rescue 
medication during migraine attacks, 
satisfaction, compliance, HIT-6 score 
NA NA 
                                                             
6 STX Med provided the Cefaly® devices, but it is stated that the study was not industry sponsored. 
7 Baseline data on 20 pts. 
8 2 pts dropped out before using e-TNS device. Baseline data on 35 pts. 
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 Russo et al. [12] (2015) DiFiore et al. [11] (2017) Vikelis et al. [13] (2017) 
Baseline patient characteristics  
(I vs. C) 
   
Mean age, yrs (SD) 32.9 (2.3) 43.7 (13.6) 45 (median), 22-62 (range) 
Sex, female:male, n 15:5 18:5 31:4 
Migraine with aura, n (%) 
Migraine without aura, n (%) 
Migraine duration,  
mean n of yrs (SD) 
Migraine attack duration  
in hrs, median (IQR) 
0 (0) 
24 (100) 
8.3 (1.7) 
 
NA 
NA 
NA 
26.4 (12.8)9 
 
NA 
NA 
NA 
NA 
 
NA 
Follow-up time, days 60 120 90 
Loss to follow-up, n (%) 4 (16.7)10 4 (17.4)11 8 (21.6) 
Efficacy 
Reduction in monthly migraine 
attacks, mean n 
Difference, mean (p-value) 
4.6/2.112 
(baseline/60 days) 
2.5 (<0.001) 
NA 
 
NA 
NA 
 
NA 
Reduction in monthly migraine 
days, mean n 
Difference, mean n (p-value) 
6.6/3.1 12 
(baseline/60 days) 
3.5 (<0.001) 
20.7/ 14.313 
(baseline/120 days) 
31.0% (NA) 
NA 
 
NA 
Reduction in monthly headache 
days, mean (SD) 
Difference, mean n (p-value) 
NA 
 
NA 
NA 
 
NA 
8.9 (4.7)/6.3 (3.5) 
(baseline/90 days) 
2 (<0.001) 
Reduction in monthly acute anti-
migraine drug intake, (n of times 
per month), mean (SD) 
Difference, mean n [%] (p-value) 
5.6 (0.4)/2.2 (0.3)14 
(baseline/60 days) 
 
3.4 [40.7] (<0.001) 
20.2/10.2 13 
(baseline/120 days) 
 
49.6% (NA) 
8.2 (4.6)/4.4 (3.3) 
(baseline/90 days) 
 
46.3% (NA) 
                                                             
  9 Mean duration of the chronic phase was 10.7 (8.7). 
10 Pts excluded from the analysis for non-compliance (compliance defined in the study as ≥2/3 of total 60 treatment days). 
11 1 pt due to keratoconjunctivitis, 3 pts due to inability to tolerate e-TNS. Efficacy reported for 19 pts who fulfilled 4-months treatment schedule. 
12 Translated from figure, as values were not explicitly reported on in the text. Unclear if mean or median. 
13 Analysis based on 19 pts. 
14 Unclear if it refers to monthly intake because the text states “total intake”. 
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 Russo et al. [12] (2015) DiFiore et al. [11] (2017) Vikelis et al. [13] (2017) 
Responder rate, reduction in 
migraine days, baseline vs. 
follow-up, % 
75 NA NA 
QoL NA NA NA 
Satisfaction, n (%)  20 (83.3)15 NA 23 (65.7) 
Compliance, n (%) 20 (83.3)16 19 (82.6) 27 (81.8) 
Safety 
SADEs, n 
Pain/intolerance to paresthesia 
(burning sensation), n (%) 
Arousal changes (insomnia, 
sleepiness/fatigue), n (%) 
Headaches after stimulation, n (%) 
Nausea after stimulation, n (%)  
Skin allergy/irritation, n (%) 
Neck tension, n (%) 
0 
0 
 
0 (0) 
 
0 (0) 
0 (0) 
0 (0) 
NA 
0 
0 
 
0 (0) 
 
1 (4.3) 
0 (0) 
0 (0) 
2 (8.7) 
0 
12 (34.3) 
 
NA 
 
NA 
NA 
NA 
NA 
e-TNS – external trigeminal nerve stimulation, ICD – implantable cardioverter defibrillator, ICHD – International Classification of Headache Disorders, IQR – inter-quartile range,  
hrs – hours, min – minutes, mITT – modified intention-to-treat, mos – months, MRI – magnetic resonance imaging, NA – data not available, pts – patients, QoL – quality of life,  
SADEs – serious adverse device effects, SD – standard deviation, yrs – years, VAS – visual analogue scale, WCD – wearable cardioverter defibrillator 
 
  
                                                             
15 Not measured, but defined by willingness to continue using e-TNS. Patients excluded due to non-compliance are part of this analysis. 
16 4 pts (16.7%) were considered non-compliant as they did not finish with ≥ 800 min of e-TNS treatment in the 60 days trial period. 
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Table A-4: e-TNS: Results from observational studies for acute treatment of episodic and chronic migraine 
 Chou et al. [14] (2017) Mann et al. [15] (2018) 
Country United States United States 
Sponsor STX Med -Cefaly
®
 Technology STX Med -Cefaly
®
 Technology 
Study design Prospective single-arm, interventional, open label trial 
(NCT02411513) 
Single center, prospective, open-label, phase 1 trial 
(NCT03217968). 
Conducted in 04/2015 – 10/2015 08/2017 – 01/2018 
Indication Acute treatment in pts with acute migraine attack  
(episodic or chronic) with or without aura 
Acute treatment in pts with single moderate or severe migraine attack  
(Grade 2 or 3) at home, pts with episodic migraine 
Intervention (I) e-TNS (pulse frequency 100 Hz, pulse width 250 μs,  
max intensity 16 mA, 60 min) 
e-TNS (pulse frequency 100 Hz, pulse width 250 μs, max intensity 16 mA,  
120 min) 
Comparator (C) none none 
Number of pts (I vs. C) 3517 6018 
Inclusion criteria Pts 18-65 yrs, episodic/chronic migraine with or without aura 
meeting ICHD-III criteria, 3+ hrs long attack, pain intensity 
stabilized for 1 hr, frontal-retro-peri-orbital headache 
Pts 18-65 yrs, ≥ 1-year history of episodic migraine with or without aura 
meeting ICHD-III criteria, migraine onset before 50 yrs of age, 2-8 moderate-
severe migraine attacks/mo in each of the 2 mos prior to screening, pts’ consent 
Exclusion criteria Pregnancy, Botox in the head in past 4 mos, supra-orbital 
nerve blocks in past 4 mos, other primary/secondary 
headache (except medication overuse), temporal/occipital 
headache pts, opioid medication use, migraine abortive 
medications in past 3 hrs, allodynia (oversensitivity to pain), 
metal or electric implants in head, cardiac pacemaker, ICD, 
WCD, pts with complicated migraine (hemiphlegic,  
basilar-type, ophthalmoplegic, migranous infarction) 
Pts’ difficulty distinguishing migraine from tension-type headache, >15 headaches 
per month (chronic migraine pts), migraine aura without headache, hemiplegic 
migraine and brainstem aura migraine, pts with supraorbital nerve blocks or Botox 
in the head in the prior 4 mos, migraine prophylaxis modification in prior 3 mos, 
other primary/secondary headache disorders (medication overuse), pts with 
opioid, alcohol or illicit drugs abuse, metallic or electric device in head, cardiac 
pacemaker, ICD, WCD, prior experience with Cefaly®, participation in other 
study in past 30 days, pts unable to self-service or bear the e-TNS stimulation 
Primary outcome measure Mean change in pain intensity after one-hour  
acute treatment compared to baseline 
Freedom from pain and from most bothersome migraine-associated symptoms 
(photophobia, phonophobia, nausea, vomiting) at 2 hrs post-acute treatment 
with e-TNS 
Secondary outcome measure Change in pain intensity after two-hour acute treatment 
compared to baseline (VAS scale), percentage of pts not 
requiring rescue medication at 2 hrs/24 hrs 
Reduction of moderate to severe migraine headache and percentage of pts 
with absence of photophobia, phonophobia, nausea, vomiting at 2 hrs from 
baseline. Measured at baseline, 2 hrs, 24 hrs, on the scale: 0 = no pain; 1 = mild 
pain; 2 = moderate pain; 3 = severe pain 
Baseline patient characteristics (I vs. C)   
Mean age, yrs (SD) 39.4 (12.5) 46.85 (10.2) 
                                                             
17 Baseline data on 30 pts. 
18 mITT analysis with 48 pts. 
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 Chou et al. [14] (2017) Mann et al. [15] (2018) 
Sex, female:male, n 24:6 43:5 
Migraine with aura, n (%) 
Migraine without aura, n (%) 
Migraine duration, yrs 
Migraine attack duration in hrs,  
median (IQR) 
Pts on medication, mean (SD) 
Other baseline symptoms: (n (%) 
 Nausea 
 Vomiting  
 Sensitivity to light 
 Sensitivity to sound 
NA 
NA 
NA 
NA 
 
NA 
 
NA 
NA 
NA 
NA 
15 (25) 
33 (55) 
>119 
NA 
 
NA 
 
11 (18.3) 
1 (1.66) 
27 (45) 
9 (15) 
Follow-up time, days 1 1 
Loss to follow-up, % 520 1221 
Efficacy 
QoL NA NA 
Satisfaction, n (%)  NA NA 
Headache pain free pts at 2/24 hrs  
post-acute treatment, n (%) 
NA/NA 17 (35.4)/12 (25) 
Freedom from nausea, vomiting, sensi-
tivity to light and sound at 2 hrs, n (%) 
NA 22 (36.7)22 
Reduction in pain score units on VAS scale 
compared to baseline at 1 hr, mean n (SD) 
-3.22 (2.4) 
p<0.001) 
NA 
Reduction in pain score units on VAS scale 
compared to baseline at 2 hrs, mean n (SD) 
-2.98 (2.31) 
p<0.001 
34 (NA) 23 
Pts on rescue medication at 2/24 hrs, n (%)  0 (0)/17 (48.6)24 NA/ 24 (40)25 
                                                             
19 Not specified. 
20 1 pt due to opioid use in past 3 mos, 4 pts due to inability to tolerate e-TNS. 
21 1 pt failed the training test, 4 pts withdrew from the study, 1 pt was lost to follow-up and 6 pts did follow the study protocol. 
22 From the results document it is unclear if 22 or 29 patients were free from the most bothersome symptoms. 
23 Number (%) of pts with pain relief at 2 hrs, not measured on VAS scale.  
24 34.6% out of 26 pts as 4 pts were lost to follow-up (not reachable at 24hrs). 
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 Chou et al. [14] (2017) Mann et al. [15] (2018) 
Compliance, n (%) NA 49 (81.7)26 
Safety 
SADEs , n (%) 
Pain/intolerance to paresthesia (burning 
sensation), n (%) 
Arousal changes (insomnia, 
sleepiness/fatigue, drowsiness), n (%) 
Headaches after stimulation, n (%) 
Nausea after stimulation, n (%)  
Dizziness, n (%) 
Vomiting, n (%) 
Pain in the jaw, n (%) 
Discomfort in teeth, n (%) 
Pain in eyes, n (%) 
Cold feet, n (%) 
Skin allergy/irritation, n (%) 
Neck tension, n (%) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
0 (0) 
0 (0) 
0 (0) 
7 (11.9) 
1 (1.7)27 
NA 
2 (3.5)27 
1 (1.7) 
1 (1.7) 
1 (1.7) 
1 (1.7) 
1 (1.7) 
1 (1.7) 
1 (1.7) 
11 (18.3) 
NA 
e-TNS – external trigeminal nerve stimulation, ICD – implantable cardioverter defibrillator, ICHD – International Classification of Headache Disorders, IQR – inter-quartile range,  
hrs – hours, min – minutes, mITT – modified intention-to-treat, mos – months, MRI – magnetic resonance imaging, NA – data not available, pts – patients, QoL – quality of life,  
SADEs – serious adverse device effects, SD – standard deviation, yrs – years, VAS – visual analogue scale, WCD – wearable cardioverter defibrillator 
  
                                                                                                                                                                                                                                                                                   
25 50 out of 48 pts as 12 were lost to follow-up. 
26 Defined as withdrawal, loss to follow-up, or violation of protocol. 
27 ADEs reported out of 59 pts 
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Risk of bias tables 
Internal validity of the included studies was judged by three independent researchers. All disagreements were solved through discussion. A more detailed description 
of the criteria used to assess the internal validity of the individual study designs can be found in the Internal Manual of the LBI-HTA [38] and in the Guidelines 
of EUnetHTA [39].  
Table A-5: Risk of bias – study level (randomised studies), see [32] 
Trial 
Adequate generation of 
randomisation sequence 
Adequate allocation 
concealment 
Blinding Selective outcome  
reporting unlikely 
No other aspects which 
increase the risk of bias 
Risk of bias – 
study level Patient Treating Physician 
Schoenen et al. [9] (2013) Unclear28 Yes Yes Yes Unclear29 Yes Moderate 
Chou et al. [10] (2018) Unclear28 Unclear30 Yes Yes Unclear31 No32 High 
 
  
                                                             
28 Insufficient information about sequence generation process. 
29 Even though it was reported that no adverse events or side effects occurred during the trial in both treatment arms, it seems unlikely. 
30 Method of concealment is not described to allow a definite judgement. 
31 Considering the sample size, there are reasons to think that not all ADEs s and SADEs were reported. 
32 Conflict of interest: study sponsored by the manufacturer. 
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Table A-6: Risk of bias – study level (case series), see [33] 
Study  
reference/ID 
Russo et al. 
[12] (2015) 
DiFiore et al. 
[11] (2017) 
Vikelis et al. 
[13] (2017) 
Chou et al.  
[14] (2017) 
Mann et al. 
[15] (2018) 
Study objective 
1. Was the hypothesis/aim/objective of the study clearly stated? Yes Yes  Yes Yes Yes 
Study design 
2. Was the study conducted prospectively? Yes Yes  Yes Yes Yes 
3. Were the cases collected in more than one centre? No Yes  Yes No No 
4. Were patients recruited consecutively? Yes Yes  Unclear Unclear Unclear 
Study population 
5. Were the characteristics of the participants included in the study described? Yes Yes  Partial Partial Yes 
6. Were the eligibility criteria (inclusion and exclusion criteria) for entry into the 
studyclearly stated? 
Partial33 Partial34 Partial34 Yes Yes 
7. Did participants enter the study at similar point in the disease? Yes Yes  No No Yes 
Intervention and co-intervention 
8. Was the intervention clearly described? Yes Yes  No35 Yes Yes 
9. Were additional interventions (co-interventions) clearly described? Yes No36 No Yes Yes 
Outcome measure 
10. Were relevant outcome measures established a priori? Yes Partial37  Partial Yes Yes 
11. Were outcome assessors blinded to the intervention that patients received?  Unclear38 Unclear38 Unclear38 Unclear38 Unclear38 
12. Were the relevant outcomes measured using appropriate objective/subjective methods? Yes39 Partial Partial Partial Partial 
13. Were the relevant outcomes measured before and after intervention? Yes40 Yes40 Yes40 Yes40 Yes40 
                                                             
33 Only the exclusion criteria were clearly stated in the study. 
34 Exclusion criteria were not explicitly mention in the study. 
35 Information on pulse frequency, pulse width and maximal intensity was missing. 
36 “Preexisting preventive and acute treatments for CM were not changed” was an insufficient explanation of co-interventions present. 
37 Only the primary endpoints were mentioned a priori. 
38 No information is given if the outcome assessors were blinded to the intervention. 
39 However, the validity of used methods to measure outcomes was unclear. 
40 Satisfaction was not measure before the intervention in any of the studies. 
  
A
p
p
en
d
ix 
LB
I-H
T
A
 | 20
18
 
6
5 
Study  
reference/ID 
Russo et al. 
[12] (2015) 
DiFiore et al. 
[11] (2017) 
Vikelis et al. 
[13] (2017) 
Chou et al.  
[14] (2017) 
Mann et al. 
[15] (2018) 
Statistical Analysis 
14. Were the statistical tests used to assess the relevant outcomes appropriate? Yes41 No42  No43 Yes No44 
Results and Conclusions 
15. Was follow-up long enough for important events and outcomes to occur?  No45 No45 No45 No45 No45 
16. Was the loss to follow-up reported? Yes Yes  Yes Yes Yes 
17. Did the study provide estimates of random variability in the data analysis of relevant 
outcomes?  
Yes Partial  No Partial No 
18. Were adverse events reported? Yes46 Yes  Yes Partial Yes 
19. Were the conclusions of the study supported by results? No47 No48  No47 No47 No47, 49 
Competing interest and source of support 
20. Were both competing interest and source of support for the study reported? Yes Yes  Yes Partial50 Partial50 
Overall Risk of bias Low Moderate High Moderate Moderate 
 
 
                                                             
41 It is not stated at what point or where parametric (paired t-test) and non-parametric (Wilcoxon sign-rank test) measures have been applied. 
42 Only descriptive statistics were used. 
43 Fisher’s exact test and the Mann-Whitney test are mentioned in the methods section, but the results fail to present any results from these tests. 
44 Only descriptive statistics were used. 
45 Unclear if of follow-up is enough for the effect of preventive treatment. It is taken for granted that TENs machines should have minor ADEs and SADEs even if applied onto the head. 
46 It was reported that no adverse events occurred in the study population, yet it is assumed otherwise. 
47 The study design cannot meet the conclusions about effectiveness. 
48 The study design cannot meet the conclusions about effectiveness and the conclusions are only made on the basis of a subgroup of patients from the results. 
49 Study not published yet, data available only at clinicaltrials.gov. 
50 Source of support for the study is unclear. 
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GRADE Evidence profile tables 
Table A-7: Evidence profile table: efficacy and safety of e-TNS for the prevention of episodic/chronic migraine patients 
Certainty assessment № of patients Effect 
Certainty Importance № of 
studies 
Study  
design 
Risk  
of bias Inconsistency Indirectness Imprecision 
Other 
considerations e-TNS Placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
Reduction in monthly migraine attacks (assessed with: mean number of days) 
1 randomised 
controlled trial 
not 
serious 
not serious seriousa seriousb none The mean reduction in the number of monthly migraine 
attacks in the IG (n=34) was 0.67 more than in the CG 
(n=33). Difference between IG and CG was p = 0.044. 
⨁⨁◯◯ 
LOW 
IMPORTANT 
Reduction in monthly migraine days (assessed with: mean) 
1 randomised 
controlled trial 
not 
serious 
not serious seriousa seriousb none The mean reduction in the number of monthly migraine 
days in the IG (n=34) was 1.74 more than in the CG (n=33). 
Difference between IG and CG was p = 0.054. 
⨁⨁◯◯ 
LOW 
CRITICAL 
Reduction of monthly headache days (assessed with: mean) 
1 randomised 
controlled trial 
not 
serious 
not serious seriousa seriousb none The mean reduction in the number of monthly headache 
days in the IG (n=34) was 2.28 more than in the CG (n=33). 
Difference between IG and CG was p = 0.041. 
⨁⨁◯◯ 
LOW 
IMPORTANT 
Reduction in the number of monthly acute antimigraine drug intake 
1 randomised 
controlled trial 
not 
serious 
not serious seriousa seriousb none The mean reduction in the number of monthly acute anti-
migraine drug intake in the IG (n=34) was 4.24 more than in 
the CG (n=33). Difference between IG and CG was p = 0.072. 
⨁⨁◯◯ 
LOW 
CRITICAL 
High or moderate satisfaction 
1 randomised 
controlled trial 
serious c not serious serious a serious b none 70.6% (IG, n=34) vs.39.4% (CG, n=33) ⨁◯◯◯ 
VERY LOW 
CRITICAL 
Serious Adverse device effects 
1 randomised 
controlled trial 
serious c not serious serious a serious b none 0/34 (IG) vs. 0 /33(CG) ⨁◯◯◯ 
VERY LOW 
CRITICAL 
Adverse device effects 
1 randomised 
controlled trial 
serious c not serious serious a serious b none 0/34 (IG) vs. 0/33 (CG) ⨁◯◯◯ 
VERY LOW 
IMPORTANT 
Abbreviations: CG = Control group, CI = Confidence interval, IG = Interventional group, n= number, pts = Patients, RCT = Randomised controlled trial, VAS = Visual Analogue Scale 
Explanations:  a Wrong comparator,  b Small sample size,  c Uncertainty about sufficient reporting of adverseevents  
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect 
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Table A-8: Evidence profile table: efficacy and safety of e-TNS for the acute treatment of episodic/chronic migraine patients 
Certainty assessment № of patients Effect 
Certainty Importance № of 
studies 
Study  
design 
Risk  
of bias Inconsistency Indirectness Imprecision 
Other 
considerations e-TNS Placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
Reductionin pain score units on scale compared to baseline at 1 hr 
1 randomised 
controlled trial 
serious 
a,b,c 
not serious  serious d serious e none  The mean improvement of IG (n=52) over CG (n=54)  
in reduction in pain score units on VAS scale compared to 
baseline at 1 hr was 1.68 (pGroup = 0.0001). 
⨁◯◯◯ 
VERY LOW 
CRITICAL 
Reduction in pain score units on scale compared to baseline at 24 hrs 
1 randomised 
controlled trial 
serious 
a,b,c 
not serious  serious d serious e none  The mean improvement of IG (n=52) over CG (n=54)  
in reduction in pain score units on VAS scale compared to 
baseline at 1 hr was 1.02 (pGroup = 0.028). 
⨁◯◯◯ 
VERY LOW 
IMPORTANT 
Reduction in pain score units on scale compared to baseline at 24 hrs 
1 randomised 
controlled trial 
serious 
a,b,c 
not serious  serious d serious e none  The mean improvement of IG (n=52) over CG (n=54)  
in reduction in pain score units on VAS scale compared to 
baseline at 1 hr was 1.08 (pGroup = 0.062). 
⨁◯◯◯ 
VERY LOW 
CRITICAL 
Patients on acute medication at 2 hrs 
1 randomised 
controlled trial 
serious 
a,b,c 
not serious  serious d serious e none  3/52 (IG) vs. 2/54 (CG)  ⨁◯◯◯ 
VERY LOW 
CRITICAL 
Patients on acute medication at 24 hrs 
1 randomised 
controlled trial 
serious 
a,b,c 
not serious serious d serious e none 18/52 (IG) vs. 21/54 (CG) ⨁◯◯◯ 
VERY LOW 
IMPORTANT 
Serious Adverse device effects 
1 randomised 
controlled trial 
serious 
a,b,c 
not serious serious d serious e none 0/52 (IG) vs. 0/54 (CG) ⨁◯◯◯ 
VERY LOW 
CRITICAL 
Adverse device effects 
1 randomised 
controlled trial 
serious 
a,b,c 
not serious serious d serious e none Intolerance to paresthesia in 3/52 (IG) vs. 1/54 (CG).  
Nausea after stimulation in 1/52 (IG) vs. 0/54 (CG) 
⨁◯◯◯ 
VERY LOW 
IMPORTANT 
Abbreviations: CG = Control group, CI = Confidence interval, IG = Interventional group, n= number, pts = Patients, RCT = Randomised controlled trial, VAS = Visual Analogue Scale 
Explanations: a Funded by the manufacturer,  b Insufficient information about sequence generation process,  c Method of concealment is not described to allow a definite judgement 
d Wrong comparator,  e Small sample size 
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect 
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Applicability table 
Table A-9: Summary table characterising the applicability of a body of studies 
Domain Description of applicability of evidence 
Population The population enrolled in the studies is similar to the target population of the intervetion in that 
both episodic as well as chronic migraine patients are included, patients are of simialr age, and the 
proportion of women is similar. However, there is a number of differences in inclusion and exclusion 
criteria between both preventive as well as acute treatment studies. The main ones are that some 
studies include while others exclude chronic migraine patients, some require treatment-naïve patients, 
while others treatment refractory, or some include while others exclude patients with medication 
overuse headche. 
Intervention External trigeminal nerve stimulation (e-TNS) (previously called also Supraorbital transcutaneous 
nerve stimulation (s-TNS) – original name changed after GMDN code to e-TNS) is the intenvention 
under assessment. Its product name is Cefaly®. 
Comparators Comparators differ for the acute treatment vs. prevention use of e-TNS. For prevention, topiramate, 
propranolol or placebo were considered comparators, while for acute treatment, triptans + NSAIDs/ 
Paracetamol were considered as comparators. 
Outcomes For the preventive use of e-TNS, the crucial outcomes considered were Reduction in monthly 
migraine days, Reduction in monthly acute antimigraine drug intake, and Satisfaction. Further 
outcomes considered were Reduction in monthly migraine attacks, Reduction in monthly headache 
days, QoL, and Compliance. For the acute treatment use of e-TNS, the crucial outcomes comsidered 
were Change in pain score units on VAS scale compared to baseline at 1/2/24 hours, Patients on acute 
antimigraine medication at 2/24 hours, and Satisfaction. Furhter outcomes considered were Headache 
pain free patients at 2/24 hours post-acute treatment, Improvement in nausea, vomiting, sensitivity 
to light and sound at 2 hours, QoL, and Compliance. 
Crucial safety outcomes considered were Serious adverse device effects, while further outcomes 
considered were Pain/intolerance to paraesthesia (burning sensation), Arousal changes (insomnia, 
sleepiness/fatigue), Headaches after stimulation, Skin allergy, Neck tension, Nausea after stimulation, 
Dizziness, Vomiting, Pain in the jaw, Discomfort in teeth, Pain in eyes, and Cold feet. 
Setting All of the studies included were either single-centre or multi-centre studies, with clinical centres 
based in Europe and the United States. The studies were specifically conducted in Belgium, Italy, 
Greece, and the US, and these contexts are considered similar to the Austrian one. Clinical settings 
were not described in all of the studies, but it is likely that all patients received-standard care at 
university hospitals.  
 
 
List of ongoing randomised controlled trials 
Table A-10: List of ongoing randomised controlled trials of e-TNS 
Identifier/ 
Trial name 
Patient 
population 
Estimated 
enrolment Intervention Comparison 
Primary 
Outcomes 
Primary 
completion 
date Sponsor 
NCT03465904/ 
A Phase III Trial 
of e-TNS for the 
Acute Treatment 
of Migraine 
(TEAM) 
Episodic 
migraine 
patients 
with or 
without 
aura 
600 e-TNS 
(Cefaly®) 
device 
Sham e-TNS 
(Cefaly®) 
device 
Pain 
Freedom  
at 2 hours. 
Most 
bothersome 
migraine-
associated 
symptom 
freedom at  
2 hours 
October 2018 STX Med – 
Cefaly® 
Technology 
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Literature search strategies 
Search strategy for Cochrane 
Search Name: External nerve stimulation for migraine 
Search Date: 07/05/2018 
ID Search 
#1 MeSH descriptor: [Migraine Disorders] explode all trees 
#2 migrain* (Word variations have been searched) 
#3 #1 or #2  
#4 MeSH descriptor: [Electric Stimulation] explode all trees 
#5 MeSH descriptor: [Electric Stimulation Therapy] explode all trees 
#6 neurostimul* (Word variations have been searched) 
#7 neuro-stimul* (Word variations have been searched) 
#8 electrostimul* (Word variations have been searched) 
#9 electro-stimul* (Word variations have been searched) 
#10 neuromodulat* (Word variations have been searched) 
#11 neuro-modulat* (Word variations have been searched) 
#12 #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11  
#13 MeSH descriptor: [Trigeminal Nerve] explode all trees 
#14 (trigemin* or tri-gemin* or supraorb* or supra-orb*) near nerve* (Word variations have been searched) 
#15 #13 or #14  
#16 #12 and #15  
#17 (transcutaneous* or trans-cutaneous* or extern*) near ((trigemin* or tri-gemin* or supraorb* or supra-
orb*) near (stimul* or neurostim* or neuro-stim*)) (Word variations have been searched) 
#18 e-TNS (Word variations have been searched) 
#19 eTNS (Word variations have been searched) 
#20 s-TNS (Word variations have been searched) 
#21 sTNS (Word variations have been searched) 
#22 t-SNS (Word variations have been searched) 
#23 tSNS (Word variations have been searched) 
#24 Cefaly (Word variations have been searched) 
#25 #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24  
#26 #3 and #25  
#27 supraorbital transcutaneous near (nerve stimul* or neurostimul* or neuro-stimul*):ti,ab,kw (Word 
variations have been searched) 
#28 #26 or #27  
Total: 23 Hits 
 
 
Search strategy for CDR 
Search Name: External nerve stimulation for migraines (MS/SW/HJ) 
Search Date:07/05/2018 
ID Search 
#1 MeSH DESCRIPTOR Migraine Disorders EXPLODE ALL TREES 
#2 (migrain*) 
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#3 #1 OR #2 
#4 MeSH DESCRIPTOR Electric Stimulation EXPLODE ALL TREES 
#5 MeSH DESCRIPTOR Electric Stimulation Therapy EXPLODE ALL TREES 
#6 (neurostimul*) 
#7 (neuro-stimul*) 
#8 (electrostimul*) 
#9 (electro-stimul*) 
#10 (neuromodulat*) 
#11 (neuro-modulat*) 
#12 ((trigemin* OR tri-gemin* OR supraorb* OR supra-orb*) NEAR nerve*) 
#13 MeSH DESCRIPTOR Trigeminal Nerve EXPLODE ALL TREES 
#14 ( (transcutaneous* OR trans-cutaneous* OR extern*) NEAR ((trigemin* OR tri-gemin* OR supraorb* OR 
supra-orb*) NEAR (stimul* OR neurostim* OR neuro-stim*))) 
#15 (e-TNS) 
#16 (eTNS) 
#17 (s-TNS) 
#18 (sTNS) 
#19 (t-SNS) 
#20 (tSNS) 
#21 (Cefaly) 
#22 #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR 
#18 OR #19 OR #20 OR #21 
#23 #3 AND #22 
#24 (supraorbital transcutaneous neurostimulation):TI 
Total:8 Hits 
 
 
Search strategy for Medline 
Search Name: External nerve stimulation for migraines (MS/SW/HJ) 
Search Date: 03/05/2018 
ID Search 
#1 exp Migraine Disorders/ (24860) 
#2 migrain*.mp. (35408) 
#3 1 or 2 (35428) 
#4 exp Electric Stimulation/ (123832) 
#5 exp Electric Stimulation Therapy/ (71107) 
#6 neuro?stimul*.mp. (2965) 
#7 electro?stimul*.mp. (3271) 
#8 neuro?modulat*.mp. (14238) 
#9 4 or 5 or 6 or 7 or 8 (206462) 
#10 exp Trigeminal Nerve/ (16014) 
#11 ((tri?geminal* or supra?orbital*) adj3 nerve*).mp. (14604) 
#12 10 or 11 (21127) 
#13 9 and 12 (1889) 
#14 ((trans?cutaneous* or extern*) adj5 ((tri?geminal* or supra?orbital*) adj3 (stimul* or neuro?stim*))).mp. 
(53) 
#15 e?TNS.ti,ab. (26) 
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#16 s?TNS.ti,ab. (142) 
#17 t?SNS.ti,ab. (52) 
#18 Cefaly.ti,ab. (14) 
#19 13 or 14 or 15 or 16 or 17 or 18 (2120) 
#20 3 and 19 (175) 
#21 remove duplicates from 20 (175) 
Total: 175 hits 
 
 
Search strategy for Embase 
Search Name: External nerve stimulation for migraines (MS/SW/HJ) 
Search Date: 03/05/2018 
ID Search 
#1 'migraine'/exp   
#2 migrain*:ti,ab 
#3 #1 OR #2  
#4 'nerve stimulation'/exp  
#5 'electrostimulation'/exp 
#6 'electrotherapy'/exp 
#7 'neuromodulation'/exp 
#8 electrostimul*:ti,ab 
#9 'electro stimul*':ti,ab 
#10 'neurostimul*':ti,ab 
#11 (neuro-modulat*) 
#12 'neuro-stimul*':ti,ab 
#13 'neuro-modulat*':ti,ab  
#14 #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 
#15 'trigeminal nerve'/exp   
#16 'supraorbital nerve'/exp   
#17 ((trigeminal* OR 'tri geminal*' OR supraorbital* OR 'supra orbital*') NEAR/3 nerve*):ti,ab 
#18 #15 OR #16 OR #17 
#19 #14 AND #18 
#20 ((transcutaneous* OR 'trans cutaneous*' OR extern*) NEAR/5 (trigeminal* OR 'tri geminal*' OR 
supraorbital* OR 'supra orbital*')):ti,ab 
#21 (transcutaneous* OR 'trans cutaneous*' OR   extern*) NEAR/5 (trigeminal* OR 'tri geminal*' OR 
supraorbital* OR 'supra orbital*') NEAR/3 
#22 'e tns':ti,ab 
#23 #3 AND #22 
#24 'etns':ti,ab 
#25 's-tns':ti,ab 
#26 't-sns':ti,ab 
#27 'tsns':ti,ab 
#28 cefaly:ti,ab 
#29 cefaly:dn 
#20 #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 
#31 #3 AND #30    
Total: 350 hits 
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Search strategy for ClinicaTrials.gov 
Date: 22/05/2018 
(Cefaly OR stimul* OR Electric Stimulation OR electrostim* OR electro-stim* OR neurostim* OR neuro-
stim* OR neuromodulat* OR neuro-modulat* OR trigemin* OR tri-gemin* OR supraorb* OR supra-orb* 
OR e-TNS OR eTNS OR s-TNS OR sTNS OR t-SNS OR tSNS ) AND Migraine [DISEASE] 
Total: 23 hits 
 
 
Search strategy for WHO-ICTRP 
Date: 22/05/2018 
Condition: Migraine  
AND 
Intervention: Cefaly OR stimul* OR Electric Stimulation OR electrostim* OR electro-stim* OR neuro-
stim* OR neuro-stim* OR neuromodulat* OR neuro-modulat* OR trigemin* OR tri-gemin* OR supra-
orb* OR supra-orb* OR e-TNS OR eTNS OR s-TNS OR sTNS OR t-SNS OR tSNS 
Total: 50 (37 further) hits 
 
 
Search strategy for EU Clinical Trials (EUdraCT) 
Date: 22/05/2018 
migrain* AND (Cefaly OR stimul* OR electric OR electrostim* OR neurostim* OR neuromodulat* OR 
trigemin* OR supraorb* OR transcutaneous* OR extern* OR electro-stim* OR neuro-stim* OR neuro-
modulat* OR tri-gemin* OR supra-orb* OR e-TNS OR eTNS OR s-TNS OR sTNS OR t-SNS OR tSNS) 
Total: 10 studies hits 
 
 

  
 
